WO2012170524A1 - Use of modified vasoactive intestinal peptides in the treatment of hypertension - Google Patents
Use of modified vasoactive intestinal peptides in the treatment of hypertension Download PDFInfo
- Publication number
- WO2012170524A1 WO2012170524A1 PCT/US2012/041092 US2012041092W WO2012170524A1 WO 2012170524 A1 WO2012170524 A1 WO 2012170524A1 US 2012041092 W US2012041092 W US 2012041092W WO 2012170524 A1 WO2012170524 A1 WO 2012170524A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- vip
- seq
- vasoactive intestinal
- intestinal peptide
- peptide
- Prior art date
Links
- 206010020772 Hypertension Diseases 0.000 title claims abstract description 37
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 title claims description 138
- 238000011282 treatment Methods 0.000 title abstract description 17
- 102400000015 Vasoactive intestinal peptide Human genes 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract description 50
- 102100038286 Vasoactive intestinal polypeptide receptor 2 Human genes 0.000 claims abstract description 47
- 101000666868 Homo sapiens Vasoactive intestinal polypeptide receptor 2 Proteins 0.000 claims abstract description 36
- 239000000203 mixture Substances 0.000 claims abstract description 26
- VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 claims description 171
- 102000055135 Vasoactive Intestinal Peptide Human genes 0.000 claims description 130
- 150000001413 amino acids Chemical group 0.000 claims description 41
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 40
- 239000002220 antihypertensive agent Substances 0.000 claims description 26
- 229940127088 antihypertensive drug Drugs 0.000 claims description 23
- 230000004927 fusion Effects 0.000 claims description 22
- 229940127291 Calcium channel antagonist Drugs 0.000 claims description 18
- 230000001225 therapeutic effect Effects 0.000 claims description 18
- 239000000480 calcium channel blocker Substances 0.000 claims description 17
- 239000002464 receptor antagonist Substances 0.000 claims description 15
- 229940044551 receptor antagonist Drugs 0.000 claims description 15
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims description 13
- 101710137651 Vasoactive intestinal polypeptide receptor 2 Proteins 0.000 claims description 12
- 239000005541 ACE inhibitor Substances 0.000 claims description 11
- 230000004872 arterial blood pressure Effects 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 229960002274 atenolol Drugs 0.000 claims description 7
- 230000037396 body weight Effects 0.000 claims description 7
- 238000011260 co-administration Methods 0.000 claims description 7
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 claims description 7
- 229960003401 ramipril Drugs 0.000 claims description 7
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical group CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 claims description 6
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 claims description 6
- 229960000528 amlodipine Drugs 0.000 claims description 6
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 6
- 238000006467 substitution reaction Methods 0.000 claims description 6
- 208000007530 Essential hypertension Diseases 0.000 claims description 5
- 230000035487 diastolic blood pressure Effects 0.000 claims description 5
- 230000035488 systolic blood pressure Effects 0.000 claims description 5
- 230000007423 decrease Effects 0.000 claims description 4
- 238000012217 deletion Methods 0.000 claims description 4
- 230000037430 deletion Effects 0.000 claims description 4
- 208000015658 resistant hypertension Diseases 0.000 claims description 4
- 230000001196 vasorelaxation Effects 0.000 claims description 4
- 210000004899 c-terminal region Anatomy 0.000 claims description 3
- 238000003780 insertion Methods 0.000 claims description 3
- 230000037431 insertion Effects 0.000 claims description 3
- 230000002195 synergetic effect Effects 0.000 claims description 3
- 230000000996 additive effect Effects 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims 1
- 230000036772 blood pressure Effects 0.000 abstract description 30
- 230000003276 anti-hypertensive effect Effects 0.000 abstract description 7
- 238000002560 therapeutic procedure Methods 0.000 abstract description 6
- 229940024606 amino acid Drugs 0.000 description 39
- 230000000694 effects Effects 0.000 description 38
- 235000001014 amino acid Nutrition 0.000 description 37
- 239000003814 drug Substances 0.000 description 37
- 108020001507 fusion proteins Proteins 0.000 description 37
- 102000037865 fusion proteins Human genes 0.000 description 32
- 229940124597 therapeutic agent Drugs 0.000 description 28
- 102100037516 Protein polybromo-1 Human genes 0.000 description 21
- 125000000539 amino acid group Chemical group 0.000 description 20
- 238000009472 formulation Methods 0.000 description 18
- 230000007704 transition Effects 0.000 description 18
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 17
- 101710137655 Vasoactive intestinal polypeptide receptor 1 Proteins 0.000 description 17
- 102100038388 Vasoactive intestinal polypeptide receptor 1 Human genes 0.000 description 17
- 108700027322 VIP-ELP fusion molecule PB1046 Proteins 0.000 description 16
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 15
- 125000005647 linker group Chemical group 0.000 description 15
- 229930182817 methionine Natural products 0.000 description 15
- 102000005962 receptors Human genes 0.000 description 15
- 108020003175 receptors Proteins 0.000 description 15
- 102000004196 processed proteins & peptides Human genes 0.000 description 14
- 229920000642 polymer Polymers 0.000 description 13
- 239000004474 valine Substances 0.000 description 13
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 12
- 238000000338 in vitro Methods 0.000 description 12
- 238000001727 in vivo Methods 0.000 description 12
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 210000002216 heart Anatomy 0.000 description 11
- 241000700159 Rattus Species 0.000 description 10
- 125000003275 alpha amino acid group Chemical group 0.000 description 10
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 10
- 229920001184 polypeptide Polymers 0.000 description 10
- 125000006850 spacer group Chemical group 0.000 description 10
- 102100039246 Elongator complex protein 1 Human genes 0.000 description 9
- 101710167754 Elongator complex protein 1 Proteins 0.000 description 9
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 9
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 8
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 230000002209 hydrophobic effect Effects 0.000 description 8
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 8
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 238000011699 spontaneously hypertensive rat Methods 0.000 description 8
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 7
- 239000004471 Glycine Substances 0.000 description 7
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 7
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 7
- 235000004279 alanine Nutrition 0.000 description 7
- 230000031018 biological processes and functions Effects 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 6
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 6
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 6
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 6
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 6
- 239000004472 Lysine Substances 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 101710181812 Methionine aminopeptidase Proteins 0.000 description 6
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 230000004087 circulation Effects 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 230000001631 hypertensive effect Effects 0.000 description 6
- 235000018977 lysine Nutrition 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 230000002685 pulmonary effect Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 238000007920 subcutaneous administration Methods 0.000 description 6
- 230000002459 sustained effect Effects 0.000 description 6
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 6
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 5
- 210000001783 ELP Anatomy 0.000 description 5
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 5
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- -1 SEQ ID NO: 17 Chemical compound 0.000 description 5
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 5
- 235000018417 cysteine Nutrition 0.000 description 5
- 239000002934 diuretic Substances 0.000 description 5
- 229940030606 diuretics Drugs 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 229960000310 isoleucine Drugs 0.000 description 5
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 230000024883 vasodilation Effects 0.000 description 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
- 239000004475 Arginine Substances 0.000 description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
- 101500027956 Homo sapiens Vasoactive intestinal peptide Proteins 0.000 description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 4
- 102000035195 Peptidases Human genes 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 4
- 239000004473 Threonine Substances 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 4
- 235000009697 arginine Nutrition 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 239000002876 beta blocker Substances 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000007385 chemical modification Methods 0.000 description 4
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 4
- 230000003205 diastolic effect Effects 0.000 description 4
- 235000013922 glutamic acid Nutrition 0.000 description 4
- 239000004220 glutamic acid Substances 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000007911 parenteral administration Methods 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 235000004400 serine Nutrition 0.000 description 4
- 238000010254 subcutaneous injection Methods 0.000 description 4
- 239000007929 subcutaneous injection Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 235000008521 threonine Nutrition 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- 102100037790 VIP peptides Human genes 0.000 description 3
- QWCKQJZIFLGMSD-UHFFFAOYSA-N alpha-aminobutyric acid Chemical compound CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 3
- 229940030600 antihypertensive agent Drugs 0.000 description 3
- 235000009582 asparagine Nutrition 0.000 description 3
- 229960001230 asparagine Drugs 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000036760 body temperature Effects 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 235000004554 glutamine Nutrition 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000002688 persistence Effects 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 230000002797 proteolythic effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 2
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102400000345 Angiotensin-2 Human genes 0.000 description 2
- 101800000733 Angiotensin-2 Proteins 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 2
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 102000002808 Pituitary adenylate cyclase-activating polypeptide Human genes 0.000 description 2
- 108010004684 Pituitary adenylate cyclase-activating polypeptide Proteins 0.000 description 2
- 102000004338 Transferrin Human genes 0.000 description 2
- 108090000901 Transferrin Proteins 0.000 description 2
- 101710128740 VIP peptides Proteins 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 238000011360 adjunctive therapy Methods 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 2
- 229950006323 angiotensin ii Drugs 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000007883 bronchodilation Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000002057 chronotropic effect Effects 0.000 description 2
- 230000007012 clinical effect Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000011278 co-treatment Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- XVOYSCVBGLVSOL-UHFFFAOYSA-N cysteic acid Chemical compound OC(=O)C(N)CS(O)(=O)=O XVOYSCVBGLVSOL-UHFFFAOYSA-N 0.000 description 2
- 230000000916 dilatatory effect Effects 0.000 description 2
- 230000010339 dilation Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000027119 gastric acid secretion Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 2
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 239000005555 hypertensive agent Substances 0.000 description 2
- 230000036543 hypotension Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 210000000663 muscle cell Anatomy 0.000 description 2
- 210000002464 muscle smooth vascular Anatomy 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 230000006320 pegylation Effects 0.000 description 2
- 239000000813 peptide hormone Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- UFTCZKMBJOPXDM-XXFCQBPRSA-N pituitary adenylate cyclase-activating polypeptide Chemical compound C([C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 UFTCZKMBJOPXDM-XXFCQBPRSA-N 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 230000009145 protein modification Effects 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 239000012581 transferrin Substances 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 108010003885 valyl-prolyl-glycyl-glycine Proteins 0.000 description 2
- 230000002227 vasoactive effect Effects 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- HMJIYCCIJYRONP-UHFFFAOYSA-N (+-)-Isradipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 HMJIYCCIJYRONP-UHFFFAOYSA-N 0.000 description 1
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- BVAUMRCGVHUWOZ-ZETCQYMHSA-N (2s)-2-(cyclohexylazaniumyl)propanoate Chemical compound OC(=O)[C@H](C)NC1CCCCC1 BVAUMRCGVHUWOZ-ZETCQYMHSA-N 0.000 description 1
- MRTPISKDZDHEQI-YFKPBYRVSA-N (2s)-2-(tert-butylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC(C)(C)C MRTPISKDZDHEQI-YFKPBYRVSA-N 0.000 description 1
- NPDBDJFLKKQMCM-SCSAIBSYSA-N (2s)-2-amino-3,3-dimethylbutanoic acid Chemical compound CC(C)(C)[C@H](N)C(O)=O NPDBDJFLKKQMCM-SCSAIBSYSA-N 0.000 description 1
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- KOHIRBRYDXPAMZ-YHBROIRLSA-N (S,R,R,R)-nebivolol Chemical compound C1CC2=CC(F)=CC=C2O[C@H]1[C@H](O)CNC[C@@H](O)[C@H]1OC2=CC=C(F)C=C2CC1 KOHIRBRYDXPAMZ-YHBROIRLSA-N 0.000 description 1
- OGNSCSPNOLGXSM-UHFFFAOYSA-N 2,4-diaminobutyric acid Chemical compound NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- HLPBVBAEIVCCLH-USJZOSNVSA-N 2-[[(2s)-2-[[2-[[(2s)-1-[(2s)-2-[[(2s)-2-amino-3-methylbutanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-3-methylbutanoyl]amino]acetic acid Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O HLPBVBAEIVCCLH-USJZOSNVSA-N 0.000 description 1
- LFTRJWKKLPVMNE-RCBQFDQVSA-N 2-[[(2s)-2-[[2-[[(2s)-1-[(2s)-2-amino-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-3-methylbutanoyl]amino]acetic acid Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O LFTRJWKKLPVMNE-RCBQFDQVSA-N 0.000 description 1
- LJGHYPLBDBRCRZ-UHFFFAOYSA-N 3-(3-aminophenyl)sulfonylaniline Chemical compound NC1=CC=CC(S(=O)(=O)C=2C=C(N)C=CC=2)=C1 LJGHYPLBDBRCRZ-UHFFFAOYSA-N 0.000 description 1
- JDXQWYKOKYUQDN-UHFFFAOYSA-N 3-hydroxypyrrolidine-2,5-dione Chemical class OC1CC(=O)NC1=O JDXQWYKOKYUQDN-UHFFFAOYSA-N 0.000 description 1
- VGHPYIHJEJAJJZ-UHFFFAOYSA-N 3-hydroxypyrrolidine-2,5-dione;pyrrole-2,5-dione Chemical class O=C1NC(=O)C=C1.OC1CC(=O)NC1=O VGHPYIHJEJAJJZ-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- 108060003345 Adrenergic Receptor Proteins 0.000 description 1
- 102000017910 Adrenergic receptor Human genes 0.000 description 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
- 241000024188 Andala Species 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 206010007558 Cardiac failure chronic Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 102000005600 Cathepsins Human genes 0.000 description 1
- 108010084457 Cathepsins Proteins 0.000 description 1
- 229940123715 Chloride channel antagonist Drugs 0.000 description 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 102100034241 Elongator complex protein 2 Human genes 0.000 description 1
- 101710167764 Elongator complex protein 2 Proteins 0.000 description 1
- 102100035074 Elongator complex protein 3 Human genes 0.000 description 1
- 102100035090 Elongator complex protein 4 Human genes 0.000 description 1
- 101710167759 Elongator complex protein 4 Proteins 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- 102000002045 Endothelin Human genes 0.000 description 1
- 108050009340 Endothelin Proteins 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 108010088842 Fibrinolysin Proteins 0.000 description 1
- 206010016803 Fluid overload Diseases 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 102400000921 Gastrin Human genes 0.000 description 1
- 108010052343 Gastrins Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 101000877382 Homo sapiens Elongator complex protein 3 Proteins 0.000 description 1
- 101000684208 Homo sapiens Prolyl endopeptidase FAP Proteins 0.000 description 1
- 101000805490 Homo sapiens VIP peptides Proteins 0.000 description 1
- 101000666856 Homo sapiens Vasoactive intestinal polypeptide receptor 1 Proteins 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- DEFJQIDDEAULHB-IMJSIDKUSA-N L-alanyl-L-alanine Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(O)=O DEFJQIDDEAULHB-IMJSIDKUSA-N 0.000 description 1
- ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- XIGSAGMEBXLVJJ-YFKPBYRVSA-N L-homocitrulline Chemical compound NC(=O)NCCCC[C@H]([NH3+])C([O-])=O XIGSAGMEBXLVJJ-YFKPBYRVSA-N 0.000 description 1
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
- 108010007859 Lisinopril Proteins 0.000 description 1
- YRAWWKUTNBILNT-FXQIFTODSA-N Met-Ala-Ala Chemical group CSCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O YRAWWKUTNBILNT-FXQIFTODSA-N 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- UWWDHYUMIORJTA-HSQYWUDLSA-N Moexipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC(OC)=C(OC)C=C2C1)C(O)=O)CC1=CC=CC=C1 UWWDHYUMIORJTA-HSQYWUDLSA-N 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 102220564276 Natural killer cells antigen CD94_K20R_mutation Human genes 0.000 description 1
- 102220564245 Natural killer cells antigen CD94_S25A_mutation Human genes 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 108010047320 Pepsinogen A Proteins 0.000 description 1
- 102100023832 Prolyl endopeptidase FAP Human genes 0.000 description 1
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 201000004239 Secondary hypertension Diseases 0.000 description 1
- 206010041277 Sodium retention Diseases 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 description 1
- 102000012088 Vasoactive Intestinal Peptide Receptors Human genes 0.000 description 1
- 108010075974 Vasoactive Intestinal Peptide Receptors Proteins 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 206010047141 Vasodilatation Diseases 0.000 description 1
- GOEMGAFJFRBGGG-UHFFFAOYSA-N acebutolol Chemical compound CCCC(=O)NC1=CC=C(OCC(O)CNC(C)C)C(C(C)=O)=C1 GOEMGAFJFRBGGG-UHFFFAOYSA-N 0.000 description 1
- 229960002122 acebutolol Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 108010056243 alanylalanine Proteins 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 229940066469 amlodipine 5 mg Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- VHYCDWMUTMEGQY-UHFFFAOYSA-N bisoprolol Chemical compound CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VHYCDWMUTMEGQY-UHFFFAOYSA-N 0.000 description 1
- 229960002781 bisoprolol Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000001593 cAMP accumulation Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000011970 concomitant therapy Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000004807 desolvation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 125000005442 diisocyanate group Chemical group 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960003580 felodipine Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 229960002490 fosinopril Drugs 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 108010069589 glycyl-valyl-glycyl-valyl-proline Proteins 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 102000056275 human VIPR1 Human genes 0.000 description 1
- 102000056273 human VIPR2 Human genes 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000008696 hypoxemic pulmonary vasoconstriction Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960004427 isradipine Drugs 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000029226 lipidation Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229960002394 lisinopril Drugs 0.000 description 1
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000000111 lower esophageal sphincter Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- VKQFCGNPDRICFG-UHFFFAOYSA-N methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1C1=CC=CC=C1[N+]([O-])=O VKQFCGNPDRICFG-UHFFFAOYSA-N 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
- 229960002237 metoprolol Drugs 0.000 description 1
- 229960005170 moexipril Drugs 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- VWPOSFSPZNDTMJ-UCWKZMIHSA-N nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 description 1
- 229960004255 nadolol Drugs 0.000 description 1
- 229960000619 nebivolol Drugs 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229960001783 nicardipine Drugs 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960000227 nisoldipine Drugs 0.000 description 1
- 238000011457 non-pharmacological treatment Methods 0.000 description 1
- 230000001129 nonadrenergic effect Effects 0.000 description 1
- 230000002536 noncholinergic effect Effects 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000001819 pancreatic juice Anatomy 0.000 description 1
- IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 description 1
- 229960002582 perindopril Drugs 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 230000009090 positive inotropic effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 230000004088 pulmonary circulation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000012887 quadratic function Methods 0.000 description 1
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 description 1
- 229960001455 quinapril Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000005932 reductive alkylation reaction Methods 0.000 description 1
- 230000004648 relaxation of smooth muscle Effects 0.000 description 1
- 230000033904 relaxation of vascular smooth muscle Effects 0.000 description 1
- 239000003169 respiratory stimulant agent Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000007320 rich medium Substances 0.000 description 1
- 102220325989 rs1555376587 Human genes 0.000 description 1
- 102220088154 rs869025539 Human genes 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 235000021023 sodium intake Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229960002256 spironolactone Drugs 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 230000035322 succinylation Effects 0.000 description 1
- 238000010613 succinylation reaction Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229960002051 trandolapril Drugs 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 108010054022 valyl-prolyl-glycyl-valyl-glycine Proteins 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Definitions
- the present invention relates to methods and pharmaceutical compositions for treating hypertension. More particularly, the present invention relates to treatment of hypertension using a combination of a modified vasoactive intestinal peptide (VIP) having a binding preference for the VPAC2 receptor and at least one anti-hypertensive drug.
- VIP vasoactive intestinal peptide
- Hypertension is a prevalent medical condition characterized by abnormally high blood pressure in the arteries. Approximately 65 million adults in the United States are affected by hypertension. See Egan er a/., 2010, JAMA 303(20): 2043-2050. The condition also affects children and teens. Clinically, hypertension is defined as a systolic pressure of 140 mm Hg or higher and a diastolic pressure of 90 mm Hg or higher. Left untreated, high blood pressure increases the risk of cardiovascular complications such as aneurysm, heart attack, heart failure, as well as renal failure.
- the present invention is based in-part on the discovery that a modified vasoactive peptide (VIP) having a binding preference for VPAC2 can provide long-acting blood pressure control synergistically with concomitant anti-hypertensive therapies. Accordingly, the present invention provides methods and compositions for treating hypertension comprising administering to a patient a VIP having a binding preference for VPAC2 and at least one anti-hypertensive drug.
- VIP vasoactive peptide
- the invention provides a method of treating hypertension in a patient, comprising administering to the patient a VIP having a binding preference for VPAC2 and at least one anti-hypertensive drug selected from a ⁇ 1 receptor antagonist, an ACE inhibitor, and a calcium channel blocker.
- the present invention is useful in treating, for example, pulmonary hypertension, uncontrolled essential hypertension, or resistant hypertension.
- the patient has chronic heart failure, and the modified VIP is an adjunctive therapy.
- the invention comprises administering the VIP having a binding preference for VPAC2 to a patient under going treatment for hypertension, including treatment with one or more of a ⁇ 1 receptor antagonist, an ACE inhibitor, and a calcium channel blocker.
- the present invention contemplates the use of a modified VIP having a binding preference for VPAC2.ln an embodiment, the modified VIP induces vasorelaxation in a patient. In another embodiment, the VIP having a binding preference for VPAC2 induces decrease of any one of systolic pressure, diastolic pressure, and mean arterial pressure.
- the VIP having a binding preference for VPAC2 may further have one or more of the following features.
- the disclosed VIP may be recombinantly or chemically modified at the N- and/or C-termini by addition of one or more amino acids, and/or by fusion to heterologous amino acid sequences. Such modifications may function to provide a modified receptor binding profile, a longer circulatory half-life or persistence in the body, and/or enhanced biological potency, when compared to the native 28 amino acid mature VIP.
- the disclosed VIP includes an N-terminal moiety that provides binding preference to VPAC2.
- the modified VIP may include additional N- terminal amino acids, such as a single amino acid at the N-terminus (e.g., Met).
- the disclosed VIP comprises the sequence MHSDAVFTDNYTRLRKOMAVKKYLNSILN (SEQ ID NO: 13).
- the disclosed VIP may alternatively have from 1 to 5 amino acid insertions, deletions, and/or substitutions (collectively with respect to SEQ ID NO:13).
- the VIP having a binding preference for VPAC2 may include a heterologous fusion partner.
- the disclosed VIP may be fused to at least one Elastin-Like-Peptide (ELP) component, which are described in detail herein.
- ELP Elastin-Like-Peptide
- the modified VIP may be fused (e.g., by recombinant means) to the N-terminus of an ELP.
- the VIP having a binding preference for VPAC2 may be administered using any suitable route of administration, such as by subcutaneous injection.
- the modified VIP is administered about once per day or about once per week.
- the modified VIP is administered at a dose of about 1 microgram to about 100 milligram per kilogram of body weight.
- the modified VIP is administered at a dose of about 10 microgram to about 10 milligram per kilogram of body weight.
- the present invention contemplates the use of one of more anti-hypertensive drugs in combination with a VIP having a binding preference for VPAC2.
- the anti-hypertensive drug and the disclosed VIP are administered separately.
- the antihypertensive drug may be a ⁇ 1 receptor antagonist, an ACE inhibitor, and/or a calcium channel blocker.
- the ⁇ 1 receptor antagonist is atenolol.
- the ACE inhibitor is ramipril.
- the calcium channel blocker is amlodipine.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising a VIP having a binding preference for VPAC2 and at least one hypertensive drug selected from a ⁇ 1 receptor antagonist, an ACE inhibitor, and a calcium channel blocker.
- the composition is formulated for once per day dosing. In another embodiment, the composition is formulated for once per week dosing. DESCRIPTION OF THE FIGURES
- Figure 1 shows the amino acid sequence of a modified VIP-ELP fusion protein (M-VIP-ELP1-120, SEQ ID NO: 14) having Met at the N-terminus and 120 ELP1 units (VPGXG, SEQ ID NO: 3) fused to the VIP at the C-terminus.
- M-VIP-ELP1-120 SEQ ID NO: 14
- VPGXG 120 ELP1 units
- Figure 2 shows the amino acid sequence of a modified VIP-ELP fusion protein (MAA-VIP-ELP1-120, SEQ ID NO: 15) having Met-Ala-Ala at the N-terminus, which is activatable to the natural mature VIP peptide, and 120 ELP1 units (VPGXG, SEQ ID NO: 3) fused to the VIP at the C-terminus.
- MAA-VIP-ELP1-120 SEQ ID NO: 15
- VPGXG 120 ELP1 units
- Figure 3 is a plasmid map of pPB1031 , which encodes ELP1-120 for convenient production of recombinant fusions.
- Figure 4 depicts pPB1046 encoding an M-VIP-ELP1-120 (SEQ ID NO: 23) fusion protein.
- Primers P0045, SEQ ID NO: 16, P0048, SEQ ID NO: 17, and P0065, SEQ ID NO: 18 for construction of the recombinant gene are shown.
- Figure 5 depicts pPB1047 encoding an MAA-VIP-ELP1-120 (SEQ ID NO: 24) fusion protein.
- Primers P0066, SEQ ID NO: 19, P0064, SEQ ID NO: 20, P0067, SEQ ID NO: 21 ) for construction of the recombinant gene are shown.
- Figure 6 shows the in vitro activity of native VIP and VIP-ELP fusion proteins PB1046 and PB1047 for VPAC2 receptor.
- Figure 7 shows the in vitro activity of native VIP and VIP-ELP fusion proteins PB1046 and PB1047 for VPAC1 receptor.
- Figure 8 shows the in vivo effect of PB1047 on rat blood pressure. Left panel shows systolic blood pressure. Right panel shows diastolic blood pressure. VIP-ELP lowers blood pressure for over a 12 hour period.
- Figure 9 is a plasmid map of pPB1 120, which encodes VIP-ELP1-120.
- Figure 10 shows the in vitro activity of native VIP and VIP-ELP fusion proteins PB1 120 and PB1046 for VPAC1 receptor.
- Figure 11 shows the in vitro activity of native VIP and VIP-ELP fusion proteins PB1 120 and PB1046 for VPAC2 receptor.
- Figure 12B shows the pharmacokinetic profile of the VIP-ELP fusion protein PB1 120 with semi-logarithmic axes.
- Figures 13A, 13B, and 13C show the average change in systolic, diastolic, and mean arterial pressure, respectively over 3 hr intervals in rats injected subcutaneously with PB1 120 at 0.1 mg/kg, 1 mg/kg, or 5 mg/kg dosages.
- Figure 13D shows the average heart rate of the subject rats over 3 hour intervals following administration of PB1 120.
- Figures 14A, 14B, and 14C show that dose-dependent sustained blood pressure control with PB1046 (VasomeraTM) is independent of ⁇ adrenergic receptor function in spontaneously hypertensive rats.
- Figures 15A, 15B, and 15C show that co-administration of PB1046 (VasomeraTM) and the anti-hypertensives - atenolol, amlodipine, or ramipril results in enhanced therapeutic effects.
- the present invention relates to methods and compositions that are useful in treating hypertension. More specifically, the present invention is based in part on the discovery that a VIP having a binding preference for VPAC2 can provide synergistic blood pressure control with concomitant anti-hypertensive therapies. Accordingly, the present invention provides specific advantages for treating hypertension such as sustained blood pressure control, enhanced efficacy of treatment, and/or reduced side effects.
- the patient has congestive heart failure, and the VIP is an adjunctive therapy.
- Vasoactive intestinal peptide is a peptide hormone containing 28 amino acid residues.
- VIP exhibits a wide variety of biological actions including, for example, systemic vasodilation, hypotension, coronary dilation, bronchodilation, and increased cardiac output in animals and humans. More specifically, VIP has a beneficial effect on blood and pulmonary pressure and has great potential as a therapeutic agent for hypertension.
- VPAC1 Vasoactive Intestinal Peptide Receptor 1
- VPAC2 Vasoactive Intestinal Peptide Receptor 2
- PACAP pituitary adenylate cyclase- activating polypeptide
- Both receptors are members of the seven-transmembrane G-protein coupled receptor family.
- VPAC1 is distributed, for example, in the central nervous system (CNS), liver, lung, intestine and T-lymphocytes.
- VPAC2 is found, for example, in the CNS, pancreas, skeletal muscle, heart, kidney, adipose tissue, testis, and stomach.
- the present invention provides methods of treating hypertension in a patient, comprising administering an effective amount of a VIP having a binding preference for VPAC2 and one or more anti-hypertensive drugs, or administering a VIP having binding preference for VPAC2 to a patient undergoing treatment with one or more of a ⁇ 1 receptor antagonist, an ACE inhibitor, and a calcium channel blocker.
- forms of hypertension treatable with the present invention include pulmonary hypertension, uncontrolled essential hypertension, and resistant hypertension.
- Pulmonary hypertension is a relatively rare but highly fatal disease characterized by progressive pulmonary arterial hypertension and increased thickening of smaller pulmonary arteries and arterioles, culminating in right ventricular (RV) failure (Said et al., 2007, Circulation 115: 1260-8).
- VIP has been linked to pulmonary and systemic circulation. With respect to the pulmonary vascular bed and its alterations in pulmonary hypertension, VIP relaxes pulmonary vascular smooth muscle from several mammalian species in vitro, neutralizes or attenuates the actions of endothelin and other vasoconstrictors, reduces hypoxic pulmonary vasoconstriction, and inhibits the proliferation of pulmonary vascular smooth muscle from patients with pulmonary hypertension.
- VIP is a cotransmitter of the physiological nonadrenergic, noncholinergic system of pulmonary vascular smooth muscle relaxation.
- Uncontrolled essential hypertension is blood pressure that is consistently higher than normal when no cause for the high blood pressure can be found.
- Essential hypertension is the most prevalent hypertension type, affecting 90-95% of hypertensive patients (Carretero et al., 2000, Circulation 101 : 329-35).
- Concentrations of VIP are decreased in stroke-prone, essential hypertensive rats (Mori et al., 1993, Jpn Heart J. 34: 785-94) and use of human VIP with sterically stabilized liposomes can normalize systemic arterial pressure in spontaneously hypertensive hamsters (Onyuksel et al., 2006, Peptides 27: 2271-5).
- Resistant hypertension is a form of high blood pressure that does not respond to treatment (i.e., blood pressure remains high even when a combination of drugs is administered).
- the causes of poor blood pressure control are numerous. The most likely causes are volume overload either due to excess sodium intake, intolerance to medications, noncompliance and secondary hypertension (Graves JW, 2000, Mayo Clin Prac 75: 278-84).
- ACE angiotensin converting enzyme
- ⁇ 1 receptor antagonists beta adrenergic antagonists
- calcium channel blockers calcium channel blockers
- Angiotensin Converting Enzyme (ACE) inhibitors block the production of angiotensin II, a hormone that normally causes vasoconstriction. As a result, the blood vessels dilate, and blood pressure is reduced. In addition, angiotensin II stimulates the release of aldosterone, a hormone which is responsible for sodium retention. Accordingly, ACE inhibitors also lower blood pressure by mimicking the effect of diuretics. Examples of ACE inhibitors include, for example, enalapril, captopril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, and trandolapril.
- ⁇ 1 receptor antagonists (beta adrenergic antagonists) block norepinephrine and epinephrine (adrenaline) from binding to beta receptors on nerves, thereby reducing heart rate. As a result, the heart beats more slowly and with less force and blood pressure is reduced. In addition, ⁇ 1 receptor antagonists also cause vasodilation, thus further reducing blood pressure. Examples of ⁇ 1 receptor antagonists include acebutolol, atenolol, bisoprolol, metoprolol, nadolol, nebivolol, and propranolol.
- Calcium channel blockers keep calcium from entering the muscle cells of the heart and blood vessels, resulting in lowered blood pressure. More specifically, calcium channel blockers relax and dilate blood vessels by affecting the muscle cells in the arterial walls. Calcium channel blockers include, for example, amlodipine, diltiazem, felodipine, isradipine, nicardipine, nifedipine, nisoldipine, and verapamil.
- Diuretics cause the body to excrete water and salt. This leads to a reduction in plasma volume, thereby lowering systemic blood pressure. Diuretics include, for example, furosemide, hydrochlorothiazide, and spironolactone.
- the present invention is based on the discovery that an increase in efficacy of treatment and/or reduction of side effects can be achieved by co-treatment with a modified vasoactive intestinal peptide having a binding preference for VPAC2 and one of more anti-hypertensive drugs such as an angiotensin converting enzyme (ACE) inhibitor, a beta adrenergic antagonists, and a calcium channel blocker.
- ACE angiotensin converting enzyme
- Vasoactive intestinal peptide is a peptide hormone containing 28 amino acid residues and is produced in many areas of the human body including the gut, pancreas and suprachiasmatic nuclei of the hypothalamus in the brain. VIP exhibits a wide variety of biological actions including systemic vasodilation, hypotension, increased cardiac output, respiratory stimulation, hyperglycemia, coronary dilation, bronchodilation in animals and humans. VIP also affects the balance of the immune system.
- VIP has an effect on several parts of the body. With respect to the digestive system, VIP may induce smooth muscle relaxation (lower esophageal sphincter, stomach, gallbladder), stimulate the secretion of water into pancreatic juice and bile, and cause inhibition of gastric acid secretion and absorption from the intestinal lumen. Its role in the intestine is to stimulate secretion of water and electrolytes, as well as dilating intestinal smooth muscle, dilating peripheral blood vessels, stimulating pancreatic bicarbonate secretion, and inhibiting gastrin-stimulated gastric acid secretion. These effects work together to increase motility. VIP has the function of stimulating pepsinogen secretion by chief cells.
- VIP has been found in the heart and has significant effects on the cardiovascular system. It causes coronary vasodilation, as well as having a positive inotropic and chronotropic effect.
- Mature VIP has 28 amino acid residues with the following sequence: HSDAVFTDNYTRLRKQMAVKKYLNSILN (SEQ ID NO: 22).
- VIP results from processing of the 170-amino acid precursor molecule prepro-VIP. Structures of VIP and exemplary analogs have been described in US Patent Nos. 4,835,252, 4,939,224, 5,141 ,924, 4,734,400, 4,605,641 , 6,080,837, 6,316,593, 5,677,419, 5,972,883, 6,489,297, 7,094,755, and 6,608,174, each of which is hereby incorporated by reference in its entirety for all purposes.
- modified VIP peptides may have an M17L substitution to prevent oxidation of Met, one or more substitutions selected from K15R, K20R and K21 R to increase proteolytic stability, and/or a substitution selected from N24A and S25A to increase proteolytic/thermal stability.
- the present invention provides modified VIP peptides that include one or more of these modifications, and with additional VIP modifications described herein.
- a modified VIP e.g., comprising SEQ ID NO: 13
- functional analogs of VIP include functional fragments truncated at the N- or C-terminus by from 1 to 10 amino acids, including by 1 , 2, 3, or up to about 5 amino acids (with respect to SEQ ID NO: 13).
- Such functional analogs may contain from 1 to 5 amino acid insertions, deletions, and/or substitutions (collectively) with respect to the native sequence (e.g., SEQ ID NO: 22), and in each case retaining the activity of the peptide (e.g., through VPAC2 binding).
- the VIP component of the modified VIP of the invention has at least about 50%, 75%, 80%, 85%, 90%, 95%, or 97% identity with the native mature sequence (SEQ ID NO: 13).
- sequence identity between two sequences can be accomplished using any alignment tool, including that described in Tatusova et al., 1999, FEMS Microbiol Lett. 174:247-250.
- the present invention provides a modified VIP molecule having receptor preference for VPAC2, as compared to unmodified VIP (e.g., a peptide consisting of the amino acid sequence of SEQ ID NO: 22).
- the modified VIP may have a relative binding preference for VPAC2 over VPAC1 of at least about 2:1 , about 5:1 , about 10:1 , about 25:1 , about 50:1 , about 100:1 , about 500:1 or more.
- the modified VIP activates the VPAC2 receptor substantially as mature, unmodified, human VIP, that is, with an EC50 within a factor of about 2 of mature, unmodified, human VIP (SEQ ID NO: 22).
- this same modified VIP is 50- or 100- fold or more less effective than mature, unmodified, human VIP in activating the VPAC1 receptor.
- modified VIP molecules may contain modified N-terminal regions, such as an addition of from 1 to about 500 amino acids to the N-terminal histidine of VIP, which may include heterologous mammalian amino acid sequence.
- the modified VIP may contain a single methionine at the N-terminal side of the natural N-terminal histidine of mature VIP. This molecule is also conveniently prepared in E. coli or other bacterial expression system, since the methionine will not be removed by E coli when the adjacent amino acid is histidine.
- the N-terminal amino acid may be any of the naturally- occurring amino acids, namely alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, serine, threonine, tryptophan, tyrosine, valine, and proline.
- amino acids namely alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, serine, threonine, tryptophan, tyrosine, valine, and proline.
- the additional sequence added to the N-terminus of VIP may be of any sequence, including biologically active and biologically inert sequences of from 1 to about 100, 1 to about 50, 1 to about 20, 1 to about 10, and 1 to about 5 amino acids.
- the N-terminus of the modified VIP may have the structure M-N, where M is methionine, and N is the N-terminus of the VIP molecule (e.g., SEQ ID No. 14, FIGURE 1 ).
- M methionine
- N the N-terminus of the VIP molecule
- This methionine supports translation of the protein in a bacterial or eukaryotic host cell.
- the modified VIP can be made in a biological system, including bacterial and yeast expression systems (e.g., E. coli). While methionine can sometimes be removed by methionine aminopeptidase (MA) in bacterial expression systems, histidine (H) is one of the least favored residues at position 2 for MA.
- MA methionine aminopeptidase
- H histidine
- the N-terminus is modified by fusion with a mammalian heterologous protein, such as a mammalian protein effective for extending half- life of therapeutic molecules.
- a mammalian heterologous protein such as a mammalian protein effective for extending half- life of therapeutic molecules.
- Such sequences may be mammalian sequences, such as albumin, transferrin, or antibody Fc sequences.
- Such sequences are described in, for example, US Patent No. 7,238,667 (particularly with respect to albumin conjugates), US Patent No. 7,176,278 (particularly with respect to transferrin conjugates), and US Patent No. 5,766,883, which are each hereby incorporated by reference in their entireties.
- N-terminal chemical modifications to the VIP N- terminus may provide receptor preference.
- Chemical modification of proteins and methods thereof are well known in the art. Non-limiting exemplary chemical modifications are PEGylation, methylglyoxalation, reductive alkylation, performic acid oxidation, succinylation, aminoethylation, and lipidation (Clifton, New Protein Techniques, New Jersey: Humana Press (1985) ISBX. 0-89603-126-8. Volume. 3 of. Methods in Molecular Biology).
- Chemical groups such as PEGylation, may be attached by modifications of cysteine, methionine, histidine, lysine, arginine, tryptophan, tyrosine, and carboxyl groups, and have been described previously (see Lundblad, Techniques in Protein Modification, CRC Press (1995)).
- the VIP of the invention contains an N-terminal and/or C- terminal bioelastic polymer component.
- a "bioelastic polymer” may exhibit an inverse temperature transition.
- Bioelastic polymers are known and described in, for example, US Patent No. 5,520,672 to Urry et al. Bioelastic polymers may be polypeptides comprising elastomeric units of pentapeptides, tetrapeptides, and/or nonapeptides (e.g. "elastin-like peptides"). Bioelastic polymers that may be used to carry out the present invention are set forth in US Patent No.
- the bioelastic polymers are polypeptides of the general formula (VPGXG) m where X is any amino acid (e.g., Ala, Leu, Phe) and m is from about 20 to about 2000, or about 50 to about 180. In exemplary embodiments, m is 60, 90, 120, 150, or 180.
- the frequency of the various amino acids as the fourth amino acid can be changed, as well as the identity of X.
- bioelastic polymers may comprise repeating elastomeric units selected from bioelastic pentapeptides and tetrapeptides, where the repeating units comprise amino acid residues selected from the group consisting of hydrophobic amino acid and glycine residues and where the repeating units exist in a conformation having a beta- turn of the formula:
- R1-R5 represent side chains of amino acid residues 1-5, and m is 0 when the repeating unit is a tetrapeptide or 1 when the repeating unit is a pentapeptide.
- Nonapeptide repeating units generally consist of sequential tetra- and pentapeptides.
- Hydrophobic amino acid residues are selected from alanine, valine, leucine, isoleucine, proline, phenylalanine, tryptophan, and methionine.
- the first amino acid residue of the repeating unit is a residue of valine, leucine, isoleucine or phenylalanine; the second amino acid residue is a residue of proline; the third amino acid residue is a residue of glycine; and the fourth amino acid residue is glycine or a very hydrophobic residue such as tryptophan, phenylalanine or tyrosine.
- Particular examples include the tetrapeptide Val-Pro-Gly-Gly, the tetrapeptide GGVP, the tetrapeptide GGFP, the tetrapeptide GGAP, the pentapeptide Val-Pro-Gly-Val- Gly, the pentapeptide GVGVP, the pentapeptide GKGVP, the pentapeptide GVGFP, the pentapeptide GFGFP, the pentapeptide GEGVP, the pentapeptide GFGVP, and the pentapeptide GVGIP. See, e.g., US Patent No. 6,699,294.
- the VIP of the invention contains an N- terminal and/or C-terminal ELP component.
- the ELP component comprises or consists of structural peptide units or sequences that are related to, or derived from, the elastin protein. Such sequences are useful for improving the properties of therapeutic proteins in one or more of bioavailability, therapeutically effective dose and/or administration frequency, biological action, formulation compatibility, resistance to proteolysis, solubility, half-life or other measure of persistence in the body subsequent to administration, and/or rate of clearance from the body. See, for example, International Patent Publication No. WO 2008/030968 which is hereby incorporated by reference in its entirety.
- the ELP component is constructed from structural units of from three to about twenty amino acids, or in some embodiments, from four to ten amino acids, such as five or six amino acids.
- the length of the individual structural units, in a particular ELP component may vary or may be uniform.
- the ELP component is constructed of a polytetra-, polypenta-, polyhexa-, polyhepta-, polyocta, and polynonapeptide motif of repeating structural units.
- Exemplary structural units include units defined by SEQ ID NOS: 1-12 (see below), which may be employed as repeating structural units, including tandem- repeating units, or may be employed in some combination, to create an ELP effective for improving the properties of the therapeutic component.
- the ELP component may comprise or consist essentially of structural unit(s) selected from SEQ ID NOS: 1-12, as defined below.
- the ELP component comprising such structural units, may be of varying sizes.
- the ELP component may comprise or consist essentially of from about 10 to about 500 structural units, or in certain embodiments about 20 to about 200 structural units, or in certain embodiments from about 50 to about 150 structural units, or from about 75 to about 130 structural units, including one or a combination of units defined by SEQ ID NOS: 1-12.
- the ELP component may comprise about 120 structural units, such as repeats of structural units defined by SEQ ID NO: 3 (defined below).
- the ELP component may have a length of from about 50 to about 2000 amino acid residues, or from about 100 to about 600 amino acid residues, or from about 200 to about 500 amino acid residues, or from about 200 to about 400 amino acid residues.
- the ELP component or in some cases the therapeutic agent, has a size of less than about 150 kDa, or less than about 100 kDa, or less than about 55 kDa, or less than about 50 kDa, or less than about 40 kDa, or less than about 30 or 25 kDa.
- the ELP component in the untransitioned state may have an extended, relatively unstructured and non-globular form so as to escape kidney filtration.
- the therapeutic agents of the invention have a molecular weight of less than the generally recognized cut-off for filtration through the kidney, such as less than about 60 kDa, or in some embodiments less than about 55, 50, 45, 40, 30, or 25 kDa, and nevertheless persist in the body by at least 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, 20-fold, or 100-fold longer than an uncoupled (e.g., unfused or unconjugated) therapeutic counterpart.
- an uncoupled e.g., unfused or unconjugated
- the ELP component does not substantially or significantly impact the biological action of the therapeutic peptide.
- the VIP with ELP fusion of the present invention may exhibit a potency (biological action) that is the same or similar to its unfused counterpart.
- the VIP with ELP fusion of the present invention may exhibit a potency or level of biological action (e.g., as tested in vitro or in vivo) of from 10- 100% of that exhibited by the unfused counterpart in the same assay.
- the (activated) VIP with ELP fusion of the present invention may exhibit a potency or level of biological action (e.g., as tested in vitro or in vivo) of at least 50%, 60%, 75%, 80%, 90%, 95% or more of that exhibited by the unfused counterpart.
- the ELP component undergoes a reversible inverse phase transition. That is, the ELP components are structurally disordered and highly soluble in water below a transition temperature (Tt), but exhibit a sharp (2-3°C range) disorder-to- order phase transition when the temperature is raised above the Tt, leading to desolvation and aggregation of the ELP components.
- Tt transition temperature
- the ELP forms insoluble polymers, when reaching sufficient size, which can be readily removed and isolated from solution by centrifugation.
- phase transition is reversible, and isolated insoluble ELPs can be completely resolubilized in buffer solution when the temperature is returned below the Tt of the ELPs.
- the therapeutic agents of the invention can, in some embodiments, be separated from other contaminating proteins to high purity using inverse transition cycling procedures, e.g., utilizing the temperature-dependent solubility of the therapeutic agent, or salt addition to the medium. Successive inverse phase transition cycles can be used to obtain a high degree of purity.
- inverse transition cycling procedures e.g., utilizing the temperature-dependent solubility of the therapeutic agent, or salt addition to the medium.
- Successive inverse phase transition cycles can be used to obtain a high degree of purity.
- other environmental variables useful for modulating the inverse transition of the therapeutic agents include pH, the addition of inorganic and organic solutes and solvents, side-chain ionization or chemical modification, and pressure.
- the ELP component does not undergo a reversible inverse phase transition, or does not undergo such a transition at a biologically relevant Tt, and thus the improvements in the biological and/or physiological properties of the molecule (as described elsewhere herein), may be entirely or substantially independent of any phase transition properties. Nevertheless, such phase transition properties may impart additional practical advantages, for example, in relation to the recovery and purification of such molecules.
- the ELP component functions to stabilize or otherwise improve the VIP component in the therapeutic composition. Subsequent to administration of the coupled VIP-ELP construct to the patient in need of the VIP therapeutic agent, the VIP component and the ELP remain coupled with one another while the VIP is therapeutically active, e.g., for the treatment and/or amelioration of hypertension.
- the ELP component(s) may be formed of structural units, including but not limited to:
- Such structural units defined by SEQ ID NOS:1-12 may form structural repeat units, or may be used in combination to form an ELP component in accordance with the invention.
- the ELP component is formed entirely (or almost entirely) of one or a combination of (e.g., 2, 3 or 4) structural units selected from SEQ ID NOS: 1-12.
- at least 75%, or at least 80%, or at least 90% of the ELP component is formed from one or a combination of structural units selected from SEQ ID NOS: 1-12, and which may be present as repeating units.
- the ELP component(s) contain repeating units, including tandem repeating units, of the pentapeptide Val-Pro-Gly-X-Gly (SEQ ID NO: 3), where X is as defined above, and where the percentage of Val-Pro-Gly-X-Gly (SEQ ID NO: 3) pentapeptide units taken with respect to the entire ELP component (which may comprise structural units other than VPGXG (SEQ ID NO: 3)) is greater than about 75%, or greater than about 85%, or greater than about 95% of the ELP component.
- the ELP component may contain motifs having a 5 to 15-unit repeat (e.g.
- exemplary motifs include VPGXG (SEQ ID NO: 3), where the guest residues are Val (which may be present in from 40% to 60% of structural units), Gly (which may be present in 20% to 40% of structural units, and Ala (which may be present in 10% to 30% of structural units).
- the repeat motif itself may be repeated, for example, from about 5 to about 20 times, such as about 8 to 15 times (e.g., about 12 times), to create an exemplary ELP component.
- the ELP component as described in this paragraph may of course be constructed from any one of the structural units defined by SEQ ID NOS: 1-12, or a combination thereof.
- An exemplary ELP component is shown in Figure 1 fused to the C-terminus of VIP.
- the ELP units may form a &tum structure that provides an elastin-like property (e.g., inverse phase transition).
- Exemplary peptide sequences suitable for creating a &turn structure are described in International Patent Publication No. WO 1996/032406, which is hereby incorporated by reference in its entirety.
- the fourth residue (X) in the elastin pentapeptide sequence, VPGXG (SEQ ID NO: 3) can be altered without eliminating the formation of a D-turn.
- the ELP components include polymeric or oligomeric repeats of the pentapeptide VPGXG (SEQ ID NO: 3), where the guest residue X is any amino acid.
- X may be a naturally occurring or non-naturally occurring amino acid.
- X is selected from alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, serine, threonine, tryptophan, tyrosine and valine.
- X is a natural amino acid other than proline or cysteine.
- the guest residue X may be a non-classical (non-genetically encoded) amino acid.
- non-classical amino acids include: D-isomers of the common amino acids, 2,4-diaminobutyric acid, I -amino isobutyric acid, A-aminobutyric acid, Abu, 2-amino butyric acid, Q-Abu, ⁇ -Ahx, 6-amino hexanoic acid, Aib, 2-amino isobutyric acid, 3-amino propionic acid, ornithine, norleucine, norvaline, hydroxyproline, sarcosine, citrulline, homocitrulline, cysteic acid, t- butylglycine, t-butylalanine, phenylglycine, cyclohexylalanine, Oalanine, fluoro
- Selection of X may be independent in each ELP structural unit (e.g., for each structural unit defined herein having a guest residue X).
- X may be independently selected for each structural unit as an amino acid having a positively charged side chain, an amino acid having a negatively charged side chain, or an amino acid having a neutral side chain, including in some embodiments, a hydrophobic side chain.
- the ELP component(s) may include polymeric or oligomeric repeats of the pentapeptides VPGXG (SEQ ID NO:3), IPGXG (SEQ ID NO:5) or LPGXG (SEQ ID NO:7), or a combination thereof, where X is as defined above.
- the structural units, or in some cases polymeric or oligomeric repeats, of the ELP sequences may be separated by one or more amino acid residues that do not eliminate the overall effect of the molecule, that is, in imparting certain improvements to the therapeutic component as described herein.
- such one or more amino acids also do not eliminate or substantially affect the phase transition properties of the ELP component (relative to the deletion of such one or more amino acids).
- ELPk [XjY j -n]
- bracketed capital letters are single letter amino acid codes and their corresponding subscripts designate the relative ratio of each guest residue X in the structural units (where applicable)
- n describes the total length of the ELP in number of the structural repeats.
- ELP1 [V5A2G3-IO] designates an ELP component containing 10 repeating units of the pentapeptide VPGXG (SEQ ID NO:3), where X is valine, alanine, and glycine at a relative ratio of 5:2:3
- ELP1 [K 1 V 7 F 1 -4] designates an ELP component containing 4 repeating units of the pentapeptide VPGXG (SEQ ID NO:3), where X is lysine, valine, and phenylalanine at a relative ratio of 1 :2:1
- ELP1 [K 1 V 7 F 1 -9] designates a polypeptide containing 9 repeating units of the pentapeptide VPGXG (SEQ ID NO:3), where X is lysine, valine, and phenylalanine at a relative ratio of 1 :7:1
- ELP1 [V 1 A 8 G 7 -10] designates an ELP component containing 10 repeating
- the Tt is a function of the hydrophobicity of the guest residue.
- ELPs can be synthesized that exhibit an inverse transition over a 0-100°C range.
- the Tt at a given ELP length may be decreased by incorporating a larger fraction of hydrophobic guest residues in the ELP sequence.
- suitable hydrophobic guest residues include valine, leucine, isoleucine, phenylalanine, tryptophan and methionine. Tyrosine, which is moderately hydrophobic, may also be used.
- the Tt may be increased by incorporating residues, such as those selected from the group consisting of: glutamic acid, cysteine, lysine, aspartate, alanine, asparagine, serine, threonine, glycine, arginine, and glutamine; preferably selected from alanine, serine, threonine and glutamic acid.
- residues such as those selected from the group consisting of: glutamic acid, cysteine, lysine, aspartate, alanine, asparagine, serine, threonine, glycine, arginine, and glutamine; preferably selected from alanine, serine, threonine and glutamic acid.
- the ELP component in some embodiments is selected or designed to provide a Tt (under physiological conditions) ranging from about 10°C to about 80°C, such as from about 35°C to about 60°C, or from about 38°C to about 45°C. In some embodiments, the Tt is greater than about 40°C or greater than about 42°C, or greater than about 45°C, or greater than about 50°C.
- the transition temperature in some embodiments, is above the body temperature of the subject or patient (e.g., > 37°C) thereby remaining soluble in vivo, or in other embodiments, the Tt is below the body temperature (e.g., ⁇ 37°C) to provide alternative advantages, such as in vivo formation of a drug depot for sustained release of the therapeutic agent. See, for example, US Patent Publication No. US 2007/0009602, which is hereby incorporated by reference in its entirety.
- the Tt of the ELP component can be modified by varying ELP chain length, as the Tt generally increases with decreasing molecular weight (MW).
- MW molecular weight
- the hydrophobicity scale developed by Urry et al. International Patent Publication No. WO 1996/032406, which is hereby incorporated by reference in its entirety
- ELP component length can be kept relatively small, while maintaining a target Tt, by incorporating a larger fraction of hydrophobic guest residues (e.g., amino acid residues having hydrophobic side chains) in the ELP sequence.
- Tt of the ELP component is affected by the identity and hydrophobicity of the guest residue, X
- additional properties of the molecule may also be affected. Such properties include, but are not limited to solubility, bioavailability, persistence, half-life, potency and safety of the molecule.
- ELP-coupled VIP agent retains a significant amount of the native VIP's biological activity, relative to unfused forms of VIP. Additionally, it is shown that ELPs exhibit long half-lives.
- ELPs can be used in accordance with the invention to substantially increase (e.g. by greater than 10%, 20%, 30%, 50%, 100%, 200% or more, in specific embodiments) the half-life of VIP, as conjugated with an ELP, in comparison to the half-life of the free (unconjugated) form of the therapeutic agent.
- the modified VIP having extended circulatory half-life may be administered from 1 to about 10 times per week, such as from 1 to about 5 times per week, or 1 to about 3 times per week.
- the modified VIP or pharmaceutical composition comprising the same may be administered about once daily, or about every other day, or about every third day, or about once a week (i.e. once weekly dosing).
- a recombinantly-produced VIP fusion protein in accordance with certain embodiments of the invention, includes the fusion component (e.g., ELP) and a VIP or an analog of VIP associated with one another by genetic fusion.
- the fusion protein may be generated by translation of a polynucleotide encoding VIP or an analog of VIP cloned in-frame with the ELP component.
- the ELP component and VIP or an analog of VIP can be fused using a linker peptide of various lengths to provide greater physical separation and allow more spatial mobility between the fused portions, and thus maximize the accessibility of VIP or an analog of VIP, for instance, for binding to its cognate receptor.
- the linker peptide may consist of amino acids that are flexible or more rigid.
- a flexible linker may include amino acids having relatively small side chains, and which may be hydrophilic.
- the flexible linker may comprise glycine and/or serine residues.
- More rigid linkers may contain, for example, more sterically hindering amino acid side chains, such as (without limitation) tyrosine or histidine.
- the linker may be less than about 50, 40, 30, 20, 10, or 5 amino acid residues.
- the linker can be covalently linked to and between VIP or an analog of VIP and an ELP component, for example, via recombinant fusion.
- the linker or peptide spacer may be protease-cleavable or non-cleavable.
- cleavable peptide spacers include, without limitation, a peptide sequence recognized by proteases (in vitro or in vivo) of varying type, such as Tev, thrombin, factor Xa, plasmin (blood proteases), metalloproteases, cathepsins, and proteases found in other corporeal compartments.
- the fusion protein may be inactive, less active, or less potent as a fusion, which is then activated upon cleavage of the spacer in vivo.
- a non-cleavable spacer may be employed.
- the non-cleavable spacer may be of any suitable type, including, for example, non-cleavable spacer moieties having the formula [(Gly) n -Ser] m , where n is from 1 to 4, inclusive, and m is from 1 to 4, inclusive.
- a short ELP sequence different than the backbone ELP could be employed instead of a linker or spacer, while accomplishing the necessary effect.
- the therapeutic agent is a recombinant fusion having a therapeutic component flanked on each terminus by an ELP component.
- At least one of said ELP components may be attached via a cleavable spacer, such that the therapeutic component is inactive, but activated in vivo by proteolytic removal of a single ELP component.
- the resulting single ELP fusion being active, and having an enhanced half-life (or other property described herein) in vivo.
- the present invention provides chemical conjugates of a VIP or an analog of VIP and the ELP component.
- the conjugates can be made by chemically coupling an ELP component to VIP or an analog of VIP by any number of methods well known in the art (See e.g., Nilsson ef a/., 2005, Ann Rev Biophys Bio Structure 34: 91-1 18).
- the chemical conjugate can be formed by covalently linking VIP or an analog of VIP to the ELP component, directly or through a short or long linker moiety, through one or more functional groups on the therapeutic proteinacious component, e.g., amine, carboxyl, phenyl, thiol or hydroxyl groups, to form a covalent conjugate.
- linkers can be used, e.g., diisocyanates, diisothiocyanates, carbodiimides, bis (hydroxysuccinimide) esters, maleimide- hydroxysuccinimide esters, glutaraldehyde and the like.
- Non-peptide chemical spacers can additionally be of any suitable type, including for example, by functional linkers described in Bioconjugate Techniques, Greg T. Hermanson, published by Academic Press, Inc., 1995, and those specified in the Cross- Linking Reagents Technical Handbook, available from Pierce Biotechnology, Inc. (Rockford, Illinois), the disclosures of which are hereby incorporated by reference, in their respective entireties.
- Illustrative chemical spacers include homobifunctional linkers that can attach to amine groups of Lys, as well as heterobifunctional linkers that can attach to Cys at one terminus, and to Lys at the other terminus.
- relatively small ELP components e.g., ELP components of less than about 30 kDa, 25 kDa, 20 kDa, 15 kDa, or 10 kDa
- room temperature or human body temperature, e.g., Tt >37°C
- two relatively small ELP components, having the same or different properties may be chemically coupled.
- Such coupling may take place in vivo, by the addition of a single cysteine residue at or around the C-terminus of the ELP.
- Such ELP components may each be fused to one or more therapeutic components, so as to increase activity or avidity at the target.
- the present invention further provides pharmaceutical compositions comprising an effective amount of a modified VIP having a binding preference for VPAC2 and at least one anti-hypertensive drug, together with a pharmaceutically acceptable carrier, diluent, or excipient.
- Such pharmaceutical compositions are effective for treating or ameliorating hypertension, as described herein.
- each of the therapeutic agents may be administered per se as well as in various forms including pharmaceutically acceptable esters, salts, and other physiologically functional derivatives thereof. It is further contemplated that the therapeutic agents may be formulated solely, or together with other therapeutic agents.
- the modified VIP having a binding preference for VPAC2 and the one or more antihypertensive drugs may be administered as a single formulation or as separation formulations.
- the formulations of the therapeutic agent include those suitable for parenteral as well as non-parenteral administration.
- Exemplary administration modalities include oral, buccal, topical, nasal, pulmonary, subcutaneous, intramuscular, and intravenous, among others.
- Formulations suitable for parenteral administration are preferred.
- the formulations comprising the therapeutic agent of the present invention may conveniently be presented in unit dosage forms and may be prepared by any of the methods well known in the art of pharmacy. Such methods generally include the step of bringing the therapeutic agents into association with a carrier which constitutes one or more accessory ingredients. Typically, the formulations are prepared by uniformly and intimately bringing the therapeutic agent into association with a liquid carrier, a finely divided solid carrier, or both, and then, if necessary, shaping the product into dosage forms of the desired formulation.
- Formulations suitable for parenteral administration conveniently comprise a sterile aqueous preparation of the therapeutic agent, which preferably is isotonic with the blood of the recipient (e.g., physiological saline solution).
- Such formulations may include suspending agents and thickening agents or other microparticulate systems which are designed to target the therapeutic agent to the circulation or one or more organs.
- the formulations may be presented in unit-dose or multi-dose form.
- the formulations of this invention may further include one or more accessory ingredient(s) selected from diluents, buffers, flavoring agents, disintegrants, surface active agents, thickeners, lubricants, preservatives (including antioxidants), and the like.
- a suitable dose of the therapeutic agent having the amino acid sequence of SEQ ID NO:14 be in a range of about 1 microgram (qg) to about 100 milligrams (mg) per kilogram body weight of the recipient, or in a range of about 10 qg to about 50 mg per kilogram body weight, or in a range of about 10 qg to about 10 mg per kilogram body weight.
- the desired dose may be presented as one dose or two or more sub-doses administered at appropriate intervals throughout the dosing period (e.g., one week, two weeks, etc).
- sub-doses can be administered in unit dosage forms, for example, containing from about 10 qg to about 500 mg, or from about 50 qg to about 200 mg, or from about 50 qg to about 100 mg of active ingredient per unit dosage form.
- the doses may be administered as a continuous infusion.
- orally administered dosages can be at least twice, e.g., 2-10 times, the dosage levels used in parenteral administration methods. Depot formulations will also allow for significantly more therapeutic agent to be delivered, such that the agent will have a sustained release over time.
- the VIP may be administered from 1 to about 10 times per week, such as from 1 to about 5 times per week, or 1 to about 3 times per week.
- the modified VIP or pharmaceutical composition comprising the same may be administered about once daily, or about every other day, or about every third day, or about once a week.
- the modified VIP is administered parenterally, such as by subcutaneous or intramuscular injection.
- the administration may be a unit dose of the modified VIP as described herein.
- the modified VIP when administered parenterally, may be administered once per day, or once or twice per week, or from once to five times per month.
- the modified VIP may be administered as a soluble fusion peptide, that persists in the circulation, as described herein, to provide sustained activity with relatively infrequent administration.
- the modified VIP may be administered as a drug depot, as also described herein, to provide a sustained release of fusion peptide into the circulation over time. See US Patent Applicaton Publication No. 2007/0009602, which is hereby incorporated by reference.
- the present invention provides methods of treating and/or ameliorating hypertension in a patient.
- the invention is for use in combination therapy, whereby a modified vasoactive intestinal peptide having a binding preference for VPAC2 is administered to a patient undergoing therapy with one or more anti-hypertensive drugs such as an angiotensin converting enzyme (ACE) inhibitor, a Dl receptor antagonist, and/or a calcium channel blocker.
- ACE angiotensin converting enzyme
- Co-administration of the modified VIP and the one or more anti-hypertensive drugs can be by concomitant administration of a single formulation or of separate formulations, e.g., a modified VIP formulation and a formulation of one or more antihypertensive drugs. Co-administration does not require the therapeutic agents to be administered simultaneously. Administration of separate formulations is considered "concomitant" if the timing of their administration is such that the pharmacological activities of the modified VIP and the one or more anti-hypertensive drugs overlap in time, thereby exerting a combined anti-hypertensive effect in the patient.
- the modified VIP with a binding preference for VPAC2 may be administered prior to, at the same time, or after the administration of the one or more anti-hypertensive drugs.
- Co-administration also does not require the therapeutic agents to be administered by the same route of administration. Rather, each therapeutic agent can be effected by any appropriate route.
- the modified VIP may be administered subcutaneously while the calcium channel blocker may be administered orally.
- the co-administration of the modified VIP with a binding preference for VPAC2 and the one or more anti-hypertensive drugs provides beneficial effects derived from the co- action of these therapeutic agents. It is contemplated that a VIP having a binding preference for VPAC2 can provide long-acting blood pressure control synergistically with concomitant anti-hypertensive therapies. Accordingly, the invention provides specific advantages such as sustained blood pressure control, enhanced efficacy of treatment, and/or reduced side effects.
- a cell-based bioassay measures the increase in intracellular cyclic adenosine monophosphate (cAMP) concentration in response to treatment with VIP or VIP-ELP fusion proteins in Chinese Hamster Ovary (CHO) cells that have been engineered to express either the human Vasoactive Intestinal Peptide Receptor 2 (VPAC2) or the human Vasoactive Intestinal Peptide Receptor 1 (VPAC1 ). Both VIP and VIP-ELP fusion proteins can stimulate production of cAMP in these cells, indicating that the fusion proteins retain the ability to bind and activate the receptor. Since the amount of cAMP accumulation in cells after receptor-mediated ligand binding and activation is directly proportional to the amount of intact peptide or fusion protein present, the assay can be used to determine bioactivity and relative potency.
- cAMP intracellular cyclic adenosine monophosphate
- PB1046 and PB1047 were tested.
- Construct PB1046 contains VIP with a Met at the N-terminus and construct PB1047 contains VIP with Ala-Ala at its N-terminus. Both constructs have ELP ⁇ 1-120) at their C- terminus.
- the activity of the constructs was tested using CHO cells expressing the VIP receptor VPAC2. After 30 minute incubations of various concentrations of the fusion proteins with the cell, the cells were lysed and the amount of cAMP produced was measured using a commercial kit.
- PB1047 was DPP-IV treated prior to the addition to the cells. Figure 6 shows the result. As shown, modified VIP fusion protein PB1046 is somewhat more active than native VIP protein, while PB1047 is less active.
- PB1046 and PB1047 were also tested using CHO cells expressing the VIP receptor VPAC1. After 30 minute incubations of various concentrations of the fusion proteins with CHO cells, cells were lysed and the amount of cAMP produced was measured using a commercial kit. PB1047 was DPP-IV treated prior to the addition to the cells. Figure 7 shows the result. This time, modified VIP fusion protein PB1046 is much less active than native VIP protein, while the relative activity of PB1047 against native VIP is about the same as it was in the test for VPAC2 receptor. These results suggest that PB1046 selectively activates VPAC2 receptor over VPAC1 receptor.
- the activity of the modified VIP-ELP fusion protein PB1047 was also tested in vivo. Specifically, effects of VIP-ELP fusion protein on blood pressure were tested. Spontaneously hypertensive rats were treated subcutaneous with PB1047 (10 mg/kg) or buffer control and their blood pressures were measured at several points after administration of the fusion protein. Five animals were used for each group and the graphs show the average and the standard deviation. PB1047 significantly reduced systolic and diastolic blood pressure in these animals for at least 12 hours post administration (see Figure 8), indicating that the VIP-ELP fusion protein is active, and can be potentially used as pharmaceuticals in treating VIP-related diseases.
- the VIP DNA sequence was cloned into vector pPB1 120 (see Figure 9) carrying the ELP1 -120 DNA sequence to give an expression cassette under the control of the T7 promoter.
- the E. coli production strain BLR was transformed with the pPB1 120 plasmid and grown in rich medium as described above. Samples of the resulting VIP-ELP1 - 120 fusion peptide, PB1 120, were purified and analyzed via SDS-PAGE.
- PB1120 was approximately 1.4 fold less active than the native VIP peptide on the VPAC1 receptor.
- PB1046 which contains an N-terminal methionine residue was approximately 1 1-fold less active than the native VIP peptide.
- PB1 120 was anywhere from 1.4- to 6-fold less active than the native VIP peptide on the VPAC1 receptor.
- FIG 11 illustrates the activity of PB1 120 for the VPAC2 receptor.
- PB1 120 show slightly less activity ( ⁇ 1.5 fold less) than the native VIP peptide for VPAC2.
- PB1046 was equipotent for VPAC2 as compared to the native peptide.
- PB1 120 was anywhere from 1.5- to 7-fold less active than the native VIP peptide on the VPAC2 receptor.
- FIG. 13A, 13B, and 13C show the average change in systolic, diastolic, and mean arterial pressure, respectively.
- Figure 13D shows the average heart rate over 3 hr intervals following administration of PB1 120.
- VPAC1 vasoactive intestinal peptide
- VPAC2 vasoactive intestinal peptide
- VasomeraTM lowered MAP by 16 ⁇ 3 % (154 ⁇ 5 mmHg vs. 184 ⁇ 6 in VEH @+6hr, P ⁇ 0.05).
- VasomeraTM triggered moderate cardio-acceleration (370 ⁇ 15 bpm at 9 mg/kg vs. 322 ⁇ 10 bpm in VEH @+2hr, P ⁇ 0.05).
- ⁇ adrenergic receptor blockade blunted VasomeraTM's chronotropic effects (308 ⁇ 3 bpm @ +2hr) while preserving/enhancing vaso-relaxation (MAP: 131 ⁇ 3 mmHg @ +6hr) see Figures 14B and 13C. No adverse clinical effects were noted.
- VasomeraTM can provide long-acting blood pressure control synergistically with concomitant therapies (such as D-adrenergic receptor blockade) and may represent a novel adjunct therapeutic agent for resistant/uncontrolled hypertensive patients.
- concomitant therapies such as D-adrenergic receptor blockade
- VasomeraTM (9 mg [177 nmol] /kg, SQ) and placebo (VEH) were assayed in untreated animals. Then, the effects of VasomeraTM were tested during concomitant oral Oadrenergic receptor blockade (+BB, atenolol 20 mg/kg/day), calcium- channel blockade (+CCB, amlodipine 5 mg/kg/day) and ACE-inhibition (+ACE, ramipril 1 mg/kg/day). Mean arterial pressure (MAP) and heart rate (HR) were measured/averaged over 24 hours both pre- and post-dosing.
- MAP mean arterial pressure
- HR heart rate
- VasomeraTM induced potent decreases in blood pressure that were sustained for up to 12 hours post-dosing (see Figure 15A). On average, VasomeraTM lowered MAP by 9 ⁇ 1 % (188 ⁇ 6 to 171 ⁇ 5 mmHg, P ⁇ 0.05). VasomeraTM's vaso-relaxation was preserved/enhanced in rats pre-treated with either atenolol (-14 ⁇ 1 %, P ⁇ 0.05), amlodipine (-13 ⁇ 2%, P ⁇ 0.05), and/or ramipril (-9 ⁇ 2%, P ⁇ 0.05) (see Figure 15B).
- VasomeraTM triggered moderate cardio-acceleration in untreated rats (+8 ⁇ 1 %, 355 ⁇ 6 to 384 ⁇ 8 bpm, P ⁇ 0.05); such chronotropy was blunted under D-adrenergic receptor blockade (+6 ⁇ 1 %, 278 ⁇ 2 to 294 ⁇ 2 bpm), but was unaffected by amlodipine or ramipril (see Figure 15C). In all cases, heart rates were lower than in controls, and no adverse clinical effects were noted.
- VasomeraTM with concomitant anti-hypertensive therapies (e.g., ⁇ adrenergic receptor blockade) can provide enhanced long-acting blood pressure control as well as reduced side effects.
- concomitant anti-hypertensive therapies e.g., ⁇ adrenergic receptor blockade
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present invention is based on the discovery that a VIP having a binding preference for VPAC2 can provide long-acting blood pressure control synergistically with concomitant anti-hypertensive therapies. Accordingly, methods and compositions useful for the treatment and/or amelioration of hypertension are provided.
Description
USE OF MODIFIED VASOACTIVE INTESTINAL PEPTIDES IN THE TREATMENT OF
HYPERTENSION
CROSS REFERENCE TO RELATED APPLICATIONS
[001] This application claims priority to and the benefit of U.S. Provisional Application No. 61/493,845, filed June 6, 2011 , which is herein incorporated by reference in its entirety.
FIELD OF THE INVENTION
[002] The present invention relates to methods and pharmaceutical compositions for treating hypertension. More particularly, the present invention relates to treatment of hypertension using a combination of a modified vasoactive intestinal peptide (VIP) having a binding preference for the VPAC2 receptor and at least one anti-hypertensive drug.
DESCRIPTION OF THE TEXT FILE SUBMITTED ELECTRONICALLY
[003] The contents of the text file submitted electronically herewith are incorporated herein by reference in their entirety: A computer readable format copy of the Sequence Listing (filename:—).
BACKGROUND
[004] Hypertension is a prevalent medical condition characterized by abnormally high blood pressure in the arteries. Approximately 65 million adults in the United States are affected by hypertension. See Egan er a/., 2010, JAMA 303(20): 2043-2050. The condition also affects children and teens. Clinically, hypertension is defined as a systolic pressure of 140 mm Hg or higher and a diastolic pressure of 90 mm Hg or higher. Left untreated, high blood pressure increases the risk of cardiovascular complications such as aneurysm, heart attack, heart failure, as well as renal failure.
[005] Current treatments for hypertension include lifestyle changes as well as drug therapy. The major classes of anti-hypertensive drugs include, for example, angiotensin converting enzyme (ACE) inhibitors, Π1 receptor antagonists (beta adrenergic antagonists), calcium channel blockers, and diuretics. However, a significant number of hypertensive
patients are resistant and do not respond to such drugs. Accordingly, there remains a continuing need for new methods of treating hypertension.
SUMMARY OF THE INVENTION
[006] The present invention is based in-part on the discovery that a modified vasoactive peptide (VIP) having a binding preference for VPAC2 can provide long-acting blood pressure control synergistically with concomitant anti-hypertensive therapies. Accordingly, the present invention provides methods and compositions for treating hypertension comprising administering to a patient a VIP having a binding preference for VPAC2 and at least one anti-hypertensive drug.
[007] In one aspect, the invention provides a method of treating hypertension in a patient, comprising administering to the patient a VIP having a binding preference for VPAC2 and at least one anti-hypertensive drug selected from a Π1 receptor antagonist, an ACE inhibitor, and a calcium channel blocker. The present invention is useful in treating, for example, pulmonary hypertension, uncontrolled essential hypertension, or resistant hypertension. In some embodiments, the patient has chronic heart failure, and the modified VIP is an adjunctive therapy. In some embodiments, the invention comprises administering the VIP having a binding preference for VPAC2 to a patient under going treatment for hypertension, including treatment with one or more of a Π1 receptor antagonist, an ACE inhibitor, and a calcium channel blocker.
[008] The present invention contemplates the use of a modified VIP having a binding preference for VPAC2.ln an embodiment, the modified VIP induces vasorelaxation in a patient. In another embodiment, the VIP having a binding preference for VPAC2 induces decrease of any one of systolic pressure, diastolic pressure, and mean arterial pressure.
[009] The VIP having a binding preference for VPAC2 may further have one or more of the following features. For example, the disclosed VIP may be recombinantly or chemically modified at the N- and/or C-termini by addition of one or more amino acids, and/or by fusion to heterologous amino acid sequences. Such modifications may function to provide a modified receptor binding profile, a longer circulatory half-life or persistence in the body, and/or enhanced biological potency, when compared to the native 28 amino acid mature VIP.
[010] In an embodiment, the disclosed VIP includes an N-terminal moiety that provides binding preference to VPAC2. For example, the modified VIP may include additional N-
terminal amino acids, such as a single amino acid at the N-terminus (e.g., Met). In an embodiment, the disclosed VIP comprises the sequence MHSDAVFTDNYTRLRKOMAVKKYLNSILN (SEQ ID NO: 13). The disclosed VIP may alternatively have from 1 to 5 amino acid insertions, deletions, and/or substitutions (collectively with respect to SEQ ID NO:13).
[011] In certain embodiments, the VIP having a binding preference for VPAC2 may include a heterologous fusion partner. In an embodiment, the disclosed VIP may be fused to at least one Elastin-Like-Peptide (ELP) component, which are described in detail herein. For example, the modified VIP may be fused (e.g., by recombinant means) to the N-terminus of an ELP.
[012] In the treatment methods, the VIP having a binding preference for VPAC2 may be administered using any suitable route of administration, such as by subcutaneous injection. In certain embodiments, the modified VIP is administered about once per day or about once per week. In an embodiment, where the modified VIP has the amino acid sequence of SEQ ID NO:14, the modified VIP is administered at a dose of about 1 microgram to about 100 milligram per kilogram of body weight. In another embodiment, the modified VIP is administered at a dose of about 10 microgram to about 10 milligram per kilogram of body weight.
[013] The present invention contemplates the use of one of more anti-hypertensive drugs in combination with a VIP having a binding preference for VPAC2. In an embodiment, the anti-hypertensive drug and the disclosed VIP are administered separately. The antihypertensive drug may be a Π1 receptor antagonist, an ACE inhibitor, and/or a calcium channel blocker. In an embodiment, the Π1 receptor antagonist is atenolol. In another embodiment, the ACE inhibitor is ramipril. In a further embodiment, the calcium channel blocker is amlodipine.
[014] In various embodiments, it is contemplated that co-treatment of the VIP having a binding preference for VPAC2 and the anti-hypertensive drug produces synergistic, or additive effects, or otherwise unexpected therapeutic advantages.
[015] In a further aspect, the present invention provides a pharmaceutical composition comprising a VIP having a binding preference for VPAC2 and at least one hypertensive drug selected from a Π1 receptor antagonist, an ACE inhibitor, and a calcium channel blocker. In a specific embodiment, the composition is formulated for once per day dosing. In another embodiment, the composition is formulated for once per week dosing.
DESCRIPTION OF THE FIGURES
[016] Figure 1 shows the amino acid sequence of a modified VIP-ELP fusion protein (M-VIP-ELP1-120, SEQ ID NO: 14) having Met at the N-terminus and 120 ELP1 units (VPGXG, SEQ ID NO: 3) fused to the VIP at the C-terminus.
[017] Figure 2 shows the amino acid sequence of a modified VIP-ELP fusion protein (MAA-VIP-ELP1-120, SEQ ID NO: 15) having Met-Ala-Ala at the N-terminus, which is activatable to the natural mature VIP peptide, and 120 ELP1 units (VPGXG, SEQ ID NO: 3) fused to the VIP at the C-terminus.
[018] Figure 3 is a plasmid map of pPB1031 , which encodes ELP1-120 for convenient production of recombinant fusions.
[019] Figure 4 depicts pPB1046 encoding an M-VIP-ELP1-120 (SEQ ID NO: 23) fusion protein. Primers (P0045, SEQ ID NO: 16, P0048, SEQ ID NO: 17, and P0065, SEQ ID NO: 18) for construction of the recombinant gene are shown.
[020] Figure 5 depicts pPB1047 encoding an MAA-VIP-ELP1-120 (SEQ ID NO: 24) fusion protein. Primers (P0066, SEQ ID NO: 19, P0064, SEQ ID NO: 20, P0067, SEQ ID NO: 21 ) for construction of the recombinant gene are shown.
[021] Figure 6 shows the in vitro activity of native VIP and VIP-ELP fusion proteins PB1046 and PB1047 for VPAC2 receptor.
[022] Figure 7 shows the in vitro activity of native VIP and VIP-ELP fusion proteins PB1046 and PB1047 for VPAC1 receptor.
[023] Figure 8 shows the in vivo effect of PB1047 on rat blood pressure. Left panel shows systolic blood pressure. Right panel shows diastolic blood pressure. VIP-ELP lowers blood pressure for over a 12 hour period.
[024] Figure 9 is a plasmid map of pPB1 120, which encodes VIP-ELP1-120.
[025] Figure 10 shows the in vitro activity of native VIP and VIP-ELP fusion proteins PB1 120 and PB1046 for VPAC1 receptor.
[026] Figure 11 shows the in vitro activity of native VIP and VIP-ELP fusion proteins PB1 120 and PB1046 for VPAC2 receptor.
[027] Figure 12A shows the pharmacokinetic profile of the VIP-ELP fusion protein PB1 120 in monkeys (n = 3) following single subcutaneous injection of 3 mg/kg with linear axes. Figure 12B shows the pharmacokinetic profile of the VIP-ELP fusion protein PB1 120 with semi-logarithmic axes.
[028] Figures 13A, 13B, and 13C show the average change in systolic, diastolic, and mean arterial pressure, respectively over 3 hr intervals in rats injected subcutaneously with PB1 120 at 0.1 mg/kg, 1 mg/kg, or 5 mg/kg dosages. Figure 13D shows the average heart rate of the subject rats over 3 hour intervals following administration of PB1 120.
[029] Figures 14A, 14B, and 14C show that dose-dependent sustained blood pressure control with PB1046 (Vasomera™) is independent of □ adrenergic receptor function in spontaneously hypertensive rats.
[030] Figures 15A, 15B, and 15C show that co-administration of PB1046 (Vasomera™) and the anti-hypertensives - atenolol, amlodipine, or ramipril results in enhanced therapeutic effects.
DETAILED DESCRIPTION OF THE INVENTION
[031] The present invention relates to methods and compositions that are useful in treating hypertension. More specifically, the present invention is based in part on the discovery that a VIP having a binding preference for VPAC2 can provide synergistic blood pressure control with concomitant anti-hypertensive therapies. Accordingly, the present invention provides specific advantages for treating hypertension such as sustained blood pressure control, enhanced efficacy of treatment, and/or reduced side effects. In some embodiments, the patient has congestive heart failure, and the VIP is an adjunctive therapy.
[032] Vasoactive intestinal peptide (VIP) is a peptide hormone containing 28 amino acid residues. VIP exhibits a wide variety of biological actions including, for example, systemic vasodilation, hypotension, coronary dilation, bronchodilation, and increased cardiac output in animals and humans. More specifically, VIP has a beneficial effect on blood and pulmonary pressure and has great potential as a therapeutic agent for hypertension.
[033] There are at least two receptors for VIP, including the Vasoactive Intestinal Peptide Receptor 1 (VPAC1 ) and the Vasoactive Intestinal Peptide Receptor 2 (VPAC2). These receptors bind both VIP and the related molecule pituitary adenylate cyclase- activating polypeptide (PACAP). Both receptors are members of the seven-transmembrane G-protein coupled receptor family. VPAC1 is distributed, for example, in the central nervous system (CNS), liver, lung, intestine and T-lymphocytes. VPAC2 is found, for example, in the CNS, pancreas, skeletal muscle, heart, kidney, adipose tissue, testis, and stomach.
[034] Nonetheless, the short half-life of VIP renders the natural peptide impractical as a pharmaceutical agent. See Pozo D, et al., Peptides 28(9): 1833-1846 (2007). Indeed, studies have shown that the half-life of VIP in blood is less than two minutes (Domschke et
al., 1978, Gut 19: 1049-53; Burhol et al., 1978, Scand J Gastroent 13: 807-813). Further, the multitude of biological effects of VIP may complicate its development for any particular indication.
[035] In various embodiments described herein, the present invention provides methods of treating hypertension in a patient, comprising administering an effective amount of a VIP having a binding preference for VPAC2 and one or more anti-hypertensive drugs, or administering a VIP having binding preference for VPAC2 to a patient undergoing treatment with one or more of a Π1 receptor antagonist, an ACE inhibitor, and a calcium channel blocker. Forms of hypertension treatable with the present invention include pulmonary hypertension, uncontrolled essential hypertension, and resistant hypertension.
[036] Pulmonary hypertension is a relatively rare but highly fatal disease characterized by progressive pulmonary arterial hypertension and increased thickening of smaller pulmonary arteries and arterioles, culminating in right ventricular (RV) failure (Said et al., 2007, Circulation 115: 1260-8). VIP has been linked to pulmonary and systemic circulation. With respect to the pulmonary vascular bed and its alterations in pulmonary hypertension, VIP relaxes pulmonary vascular smooth muscle from several mammalian species in vitro, neutralizes or attenuates the actions of endothelin and other vasoconstrictors, reduces hypoxic pulmonary vasoconstriction, and inhibits the proliferation of pulmonary vascular smooth muscle from patients with pulmonary hypertension. Furthermore, VIP is a cotransmitter of the physiological nonadrenergic, noncholinergic system of pulmonary vascular smooth muscle relaxation.
[037] Uncontrolled essential hypertension is blood pressure that is consistently higher than normal when no cause for the high blood pressure can be found. Essential hypertension is the most prevalent hypertension type, affecting 90-95% of hypertensive patients (Carretero et al., 2000, Circulation 101 : 329-35). Concentrations of VIP are decreased in stroke-prone, essential hypertensive rats (Mori et al., 1993, Jpn Heart J. 34: 785-94) and use of human VIP with sterically stabilized liposomes can normalize systemic arterial pressure in spontaneously hypertensive hamsters (Onyuksel et al., 2006, Peptides 27: 2271-5).
[038] Resistant hypertension is a form of high blood pressure that does not respond to treatment (i.e., blood pressure remains high even when a combination of drugs is administered). The causes of poor blood pressure control are numerous. The most likely
causes are volume overload either due to excess sodium intake, intolerance to medications, noncompliance and secondary hypertension (Graves JW, 2000, Mayo Clin Prac 75: 278-84).
[039] Current treatments for hypertension include lifestyle changes as well as drug therapy. Of the non-pharmacological treatments for hypertension, weight reduction and salt restriction have been considered to be the most successful. However, a number of medications are available for those patients whose blood pressure cannot be maintained in an acceptable range by non-pharmacological means. The major classes of antihypertensive drugs include, for example, angiotensin converting enzyme (ACE) inhibitors, Π1 receptor antagonists (beta adrenergic antagonists), calcium channel blockers, and diuretics.
[040] Angiotensin Converting Enzyme (ACE) inhibitors block the production of angiotensin II, a hormone that normally causes vasoconstriction. As a result, the blood vessels dilate, and blood pressure is reduced. In addition, angiotensin II stimulates the release of aldosterone, a hormone which is responsible for sodium retention. Accordingly, ACE inhibitors also lower blood pressure by mimicking the effect of diuretics. Examples of ACE inhibitors include, for example, enalapril, captopril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, and trandolapril.
[041] Π1 receptor antagonists (beta adrenergic antagonists) block norepinephrine and epinephrine (adrenaline) from binding to beta receptors on nerves, thereby reducing heart rate. As a result, the heart beats more slowly and with less force and blood pressure is reduced. In addition, Π1 receptor antagonists also cause vasodilation, thus further reducing blood pressure. Examples of Π1 receptor antagonists include acebutolol, atenolol, bisoprolol, metoprolol, nadolol, nebivolol, and propranolol.
[042] Calcium channel blockers keep calcium from entering the muscle cells of the heart and blood vessels, resulting in lowered blood pressure. More specifically, calcium channel blockers relax and dilate blood vessels by affecting the muscle cells in the arterial walls. Calcium channel blockers include, for example, amlodipine, diltiazem, felodipine, isradipine, nicardipine, nifedipine, nisoldipine, and verapamil.
[043] Diuretics cause the body to excrete water and salt. This leads to a reduction in plasma volume, thereby lowering systemic blood pressure. Diuretics include, for example, furosemide, hydrochlorothiazide, and spironolactone.
[044] All of the aforementioned hypertensive drugs have side effects. Further, a significant number of hypertensive patients are resistant and do not respond to such drugs. The present invention is based on the discovery that an increase in efficacy of treatment and/or reduction of side effects can be achieved by co-treatment with a modified vasoactive
intestinal peptide having a binding preference for VPAC2 and one of more anti-hypertensive drugs such as an angiotensin converting enzyme (ACE) inhibitor, a beta adrenergic antagonists, and a calcium channel blocker.
[045] Vasoactive intestinal peptide (VIP) is a peptide hormone containing 28 amino acid residues and is produced in many areas of the human body including the gut, pancreas and suprachiasmatic nuclei of the hypothalamus in the brain. VIP exhibits a wide variety of biological actions including systemic vasodilation, hypotension, increased cardiac output, respiratory stimulation, hyperglycemia, coronary dilation, bronchodilation in animals and humans. VIP also affects the balance of the immune system.
[046] VIP has an effect on several parts of the body. With respect to the digestive system, VIP may induce smooth muscle relaxation (lower esophageal sphincter, stomach, gallbladder), stimulate the secretion of water into pancreatic juice and bile, and cause inhibition of gastric acid secretion and absorption from the intestinal lumen. Its role in the intestine is to stimulate secretion of water and electrolytes, as well as dilating intestinal smooth muscle, dilating peripheral blood vessels, stimulating pancreatic bicarbonate secretion, and inhibiting gastrin-stimulated gastric acid secretion. These effects work together to increase motility. VIP has the function of stimulating pepsinogen secretion by chief cells.
[047] VIP has been found in the heart and has significant effects on the cardiovascular system. It causes coronary vasodilation, as well as having a positive inotropic and chronotropic effect.
[048] Mature VIP has 28 amino acid residues with the following sequence: HSDAVFTDNYTRLRKQMAVKKYLNSILN (SEQ ID NO: 22). VIP results from processing of the 170-amino acid precursor molecule prepro-VIP. Structures of VIP and exemplary analogs have been described in US Patent Nos. 4,835,252, 4,939,224, 5,141 ,924, 4,734,400, 4,605,641 , 6,080,837, 6,316,593, 5,677,419, 5,972,883, 6,489,297, 7,094,755, and 6,608,174, each of which is hereby incorporated by reference in its entirety for all purposes.
[049] A number of mutations to improve peptide stability against proteases etc. are detailed in the literature (see Onune et al., Eur. J. Pharm. Biopharm. 2009, which is hereby incorporated by reference in its entirety for all purposes). These modified VIP peptides may have an M17L substitution to prevent oxidation of Met, one or more substitutions selected from K15R, K20R and K21 R to increase proteolytic stability, and/or a substitution selected from N24A and S25A to increase proteolytic/thermal stability. The present invention
provides modified VIP peptides that include one or more of these modifications, and with additional VIP modifications described herein.
[050] In various embodiments described herein, a modified VIP (e.g., comprising SEQ ID NO: 13) (or a functional analog as described herein) is provided. Generally, functional analogs of VIP, include functional fragments truncated at the N- or C-terminus by from 1 to 10 amino acids, including by 1 , 2, 3, or up to about 5 amino acids (with respect to SEQ ID NO: 13). Such functional analogs may contain from 1 to 5 amino acid insertions, deletions, and/or substitutions (collectively) with respect to the native sequence (e.g., SEQ ID NO: 22), and in each case retaining the activity of the peptide (e.g., through VPAC2 binding). Such activity may be confirmed or assayed using any available assay, including an assay described herein, and including any suitable assay to determine or quantify an activity described in Delgado et ai, 2004, Pharmacol. Reviews 56(2):249-290. In these or other embodiments, the VIP component of the modified VIP of the invention has at least about 50%, 75%, 80%, 85%, 90%, 95%, or 97% identity with the native mature sequence (SEQ ID NO: 13). The determination of sequence identity between two sequences (e.g., between a native sequence and a functional analog) can be accomplished using any alignment tool, including that described in Tatusova et al., 1999, FEMS Microbiol Lett. 174:247-250.
[051] In one aspect, the present invention provides a modified VIP molecule having receptor preference for VPAC2, as compared to unmodified VIP (e.g., a peptide consisting of the amino acid sequence of SEQ ID NO: 22). For example, the modified VIP may have a relative binding preference for VPAC2 over VPAC1 of at least about 2:1 , about 5:1 , about 10:1 , about 25:1 , about 50:1 , about 100:1 , about 500:1 or more. For example, in certain embodiments, the modified VIP activates the VPAC2 receptor substantially as mature, unmodified, human VIP, that is, with an EC50 within a factor of about 2 of mature, unmodified, human VIP (SEQ ID NO: 22). However, this same modified VIP is 50- or 100- fold or more less effective than mature, unmodified, human VIP in activating the VPAC1 receptor.
[052] Such modified VIP molecules may contain modified N-terminal regions, such as an addition of from 1 to about 500 amino acids to the N-terminal histidine of VIP, which may include heterologous mammalian amino acid sequence. For example, the modified VIP may contain a single methionine at the N-terminal side of the natural N-terminal histidine of mature VIP. This molecule is also conveniently prepared in E. coli or other bacterial expression system, since the methionine will not be removed by E coli when the adjacent amino acid is histidine. Alternatively, the N-terminal amino acid may be any of the naturally- occurring amino acids, namely alanine, arginine, asparagine, aspartic acid, cysteine,
glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, serine, threonine, tryptophan, tyrosine, valine, and proline.
[053] The additional sequence added to the N-terminus of VIP may be of any sequence, including biologically active and biologically inert sequences of from 1 to about 100, 1 to about 50, 1 to about 20, 1 to about 10, and 1 to about 5 amino acids.
[054] The N-terminus of the modified VIP may have the structure M-N, where M is methionine, and N is the N-terminus of the VIP molecule (e.g., SEQ ID No. 14, FIGURE 1 ). This methionine supports translation of the protein in a bacterial or eukaryotic host cell. Thus, the modified VIP can be made in a biological system, including bacterial and yeast expression systems (e.g., E. coli). While methionine can sometimes be removed by methionine aminopeptidase (MA) in bacterial expression systems, histidine (H) is one of the least favored residues at position 2 for MA.
[055] In still other embodiments, the N-terminus is modified by fusion with a mammalian heterologous protein, such as a mammalian protein effective for extending half- life of therapeutic molecules. Such sequences may be mammalian sequences, such as albumin, transferrin, or antibody Fc sequences. Such sequences are described in, for example, US Patent No. 7,238,667 (particularly with respect to albumin conjugates), US Patent No. 7,176,278 (particularly with respect to transferrin conjugates), and US Patent No. 5,766,883, which are each hereby incorporated by reference in their entireties.
[056] In these or other embodiments, N-terminal chemical modifications to the VIP N- terminus may provide receptor preference. Chemical modification of proteins and methods thereof are well known in the art. Non-limiting exemplary chemical modifications are PEGylation, methylglyoxalation, reductive alkylation, performic acid oxidation, succinylation, aminoethylation, and lipidation (Clifton, New Protein Techniques, New Jersey: Humana Press (1985) ISBX. 0-89603-126-8. Volume. 3 of. Methods in Molecular Biology). Chemical groups, such as PEGylation, may be attached by modifications of cysteine, methionine, histidine, lysine, arginine, tryptophan, tyrosine, and carboxyl groups, and have been described previously (see Lundblad, Techniques in Protein Modification, CRC Press (1995)).
Fusions to Bioelastic Polymers
[057] In some embodiments, the VIP of the invention contains an N-terminal and/or C- terminal bioelastic polymer component. A "bioelastic polymer" may exhibit an inverse temperature transition. Bioelastic polymers are known and described in, for example, US Patent No. 5,520,672 to Urry et al. Bioelastic polymers may be polypeptides comprising elastomeric units of pentapeptides, tetrapeptides, and/or nonapeptides (e.g. "elastin-like
peptides"). Bioelastic polymers that may be used to carry out the present invention are set forth in US Patent No. 4,474,851 , which describes a number of tetrapeptide and pentapeptide repeating units that can be used to form a bioelastic polymer. Specific bioelastic polymers are also described in US Patent Nos. 4,132,746; 4,187,852; 4,500,700; 4,589,882; and 4,870,055. Still other examples of bioelastic polymers are set forth in US Patent No. 6,699,294, US Patent No. 6,753,31 1 , and US Patent No. 6,063,061. The structures of such bioelastic polymers are hereby incorporated by reference.
[058] In one embodiment, the bioelastic polymers are polypeptides of the general formula (VPGXG)m where X is any amino acid (e.g., Ala, Leu, Phe) and m is from about 20 to about 2000, or about 50 to about 180. In exemplary embodiments, m is 60, 90, 120, 150, or 180. The frequency of the various amino acids as the fourth amino acid can be changed, as well as the identity of X.
[059] For example, bioelastic polymers may comprise repeating elastomeric units selected from bioelastic pentapeptides and tetrapeptides, where the repeating units comprise amino acid residues selected from the group consisting of hydrophobic amino acid and glycine residues and where the repeating units exist in a conformation having a beta- turn of the formula:
wherein R1-R5 represent side chains of amino acid residues 1-5, and m is 0 when the repeating unit is a tetrapeptide or 1 when the repeating unit is a pentapeptide. Nonapeptide repeating units generally consist of sequential tetra- and pentapeptides. Hydrophobic amino acid residues are selected from alanine, valine, leucine, isoleucine, proline, phenylalanine, tryptophan, and methionine. In many cases, the first amino acid residue of the repeating unit is a residue of valine, leucine, isoleucine or phenylalanine; the second amino acid residue is a residue of proline; the third amino acid residue is a residue of glycine; and the fourth amino acid residue is glycine or a very hydrophobic residue such as tryptophan, phenylalanine or tyrosine. Particular examples include the tetrapeptide Val-Pro-Gly-Gly, the tetrapeptide GGVP, the tetrapeptide GGFP, the tetrapeptide GGAP, the pentapeptide Val-Pro-Gly-Val-
Gly, the pentapeptide GVGVP, the pentapeptide GKGVP, the pentapeptide GVGFP, the pentapeptide GFGFP, the pentapeptide GEGVP, the pentapeptide GFGVP, and the pentapeptide GVGIP. See, e.g., US Patent No. 6,699,294.
[060] In certain exemplary embodiments, the VIP of the invention contains an N- terminal and/or C-terminal ELP component. The ELP component comprises or consists of structural peptide units or sequences that are related to, or derived from, the elastin protein. Such sequences are useful for improving the properties of therapeutic proteins in one or more of bioavailability, therapeutically effective dose and/or administration frequency, biological action, formulation compatibility, resistance to proteolysis, solubility, half-life or other measure of persistence in the body subsequent to administration, and/or rate of clearance from the body. See, for example, International Patent Publication No. WO 2008/030968 which is hereby incorporated by reference in its entirety.
[061] When the ELP is positioned at the C-terminus of VIP, additional modifications may be made at the VIP N-terminus, such as the addition of one or more amino acids, as described above. In alternative embodiments, there are no such modifications at the VIP N- terminus.
[062] The ELP component is constructed from structural units of from three to about twenty amino acids, or in some embodiments, from four to ten amino acids, such as five or six amino acids. The length of the individual structural units, in a particular ELP component, may vary or may be uniform. In certain embodiments, the ELP component is constructed of a polytetra-, polypenta-, polyhexa-, polyhepta-, polyocta, and polynonapeptide motif of repeating structural units. Exemplary structural units include units defined by SEQ ID NOS: 1-12 (see below), which may be employed as repeating structural units, including tandem- repeating units, or may be employed in some combination, to create an ELP effective for improving the properties of the therapeutic component. Thus, the ELP component may comprise or consist essentially of structural unit(s) selected from SEQ ID NOS: 1-12, as defined below.
[063] The ELP component, comprising such structural units, may be of varying sizes. For example, the ELP component may comprise or consist essentially of from about 10 to about 500 structural units, or in certain embodiments about 20 to about 200 structural units, or in certain embodiments from about 50 to about 150 structural units, or from about 75 to about 130 structural units, including one or a combination of units defined by SEQ ID NOS: 1-12. The ELP component may comprise about 120 structural units, such as repeats of structural units defined by SEQ ID NO: 3 (defined below). Thus, the ELP component may
have a length of from about 50 to about 2000 amino acid residues, or from about 100 to about 600 amino acid residues, or from about 200 to about 500 amino acid residues, or from about 200 to about 400 amino acid residues.
[064] In some embodiments, the ELP component, or in some cases the therapeutic agent, has a size of less than about 150 kDa, or less than about 100 kDa, or less than about 55 kDa, or less than about 50 kDa, or less than about 40 kDa, or less than about 30 or 25 kDa.
[065] In some embodiments, the ELP component in the untransitioned state may have an extended, relatively unstructured and non-globular form so as to escape kidney filtration. In such embodiments, the therapeutic agents of the invention have a molecular weight of less than the generally recognized cut-off for filtration through the kidney, such as less than about 60 kDa, or in some embodiments less than about 55, 50, 45, 40, 30, or 25 kDa, and nevertheless persist in the body by at least 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, 20-fold, or 100-fold longer than an uncoupled (e.g., unfused or unconjugated) therapeutic counterpart.
[066] In these or other embodiments, the ELP component does not substantially or significantly impact the biological action of the therapeutic peptide. Thus, the VIP with ELP fusion of the present invention may exhibit a potency (biological action) that is the same or similar to its unfused counterpart. The VIP with ELP fusion of the present invention may exhibit a potency or level of biological action (e.g., as tested in vitro or in vivo) of from 10- 100% of that exhibited by the unfused counterpart in the same assay. In various embodiments, the (activated) VIP with ELP fusion of the present invention may exhibit a potency or level of biological action (e.g., as tested in vitro or in vivo) of at least 50%, 60%, 75%, 80%, 90%, 95% or more of that exhibited by the unfused counterpart.
[067] In certain embodiments, the ELP component undergoes a reversible inverse phase transition. That is, the ELP components are structurally disordered and highly soluble in water below a transition temperature (Tt), but exhibit a sharp (2-3°C range) disorder-to- order phase transition when the temperature is raised above the Tt, leading to desolvation and aggregation of the ELP components. For example, the ELP forms insoluble polymers, when reaching sufficient size, which can be readily removed and isolated from solution by centrifugation. Such phase transition is reversible, and isolated insoluble ELPs can be completely resolubilized in buffer solution when the temperature is returned below the Tt of the ELPs. Thus, the therapeutic agents of the invention can, in some embodiments, be separated from other contaminating proteins to high purity using inverse transition cycling procedures, e.g., utilizing the temperature-dependent solubility of the therapeutic agent, or
salt addition to the medium. Successive inverse phase transition cycles can be used to obtain a high degree of purity. In addition to temperature and ionic strength, other environmental variables useful for modulating the inverse transition of the therapeutic agents include pH, the addition of inorganic and organic solutes and solvents, side-chain ionization or chemical modification, and pressure.
[068] In certain embodiments, the ELP component does not undergo a reversible inverse phase transition, or does not undergo such a transition at a biologically relevant Tt, and thus the improvements in the biological and/or physiological properties of the molecule (as described elsewhere herein), may be entirely or substantially independent of any phase transition properties. Nevertheless, such phase transition properties may impart additional practical advantages, for example, in relation to the recovery and purification of such molecules.
[069] In the practice of the present invention, the ELP component functions to stabilize or otherwise improve the VIP component in the therapeutic composition. Subsequent to administration of the coupled VIP-ELP construct to the patient in need of the VIP therapeutic agent, the VIP component and the ELP remain coupled with one another while the VIP is therapeutically active, e.g., for the treatment and/or amelioration of hypertension.
[070] In certain embodiments, the ELP component(s) may be formed of structural units, including but not limited to:
(a) the tetrapeptide Val-Pro-Gly-Gly, or VPGG (SEQ ID NO: 1 );
(b) the tetrapeptide lle-Pro-Gly-Gly, or IPGG (SEQ ID NO: 2);
(c) the pentapeptide Val-Pro-Gly-X-Gly (SEQ ID NO: 3), or VPGXG, where X is any natural or non-natural amino acid residue, and where X optionally varies among polymeric or oligomeric repeats;
(d) the pentapeptide Ala-Val-Gly-Val-Pro, or AVGVP (SEQ ID NO: 4);
(e) the pentapeptide lle-Pro-Gly-X-Gly, or IPGXG (SEQ ID NO: 5), where X is any natural or non-natural amino acid residue, and where X optionally varies among polymeric or oligomeric repeats;
(e) the pentapeptide lle-Pro-Gly-Val-Gly, or IPGVG (SEQ ID NO: 6);
(f) the pentapeptide Leu-Pro-Gly-X-Gly, or LPGXG (SEQ ID NO: 7), where X is any natural or non-natural amino acid residue, and where X optionally varies among polymeric or oligomeric repeats;
(g) the pentapeptide Leu-Pro-Gly-Val-Gly, or LPGVG (SEQ ID NO: 8);
(h) the hexapeptide Val-Ala-Pro-Gly-Val-Gly, or VAPGVG (SEQ ID NO: 9);
(I) the octapeptide Gly-Val-Gly-Val-Pro-Gly-Val-Gly, or GVGVPGVG (SEQ ID NO: 10);
(J) the nonapeptide Val-Pro-Gly-Phe-Gly-Val-Gly-Ala-Gly, or VPGFGVGAG (SEQ ID NO: 1 1 ); and
(K) the nonapeptides Val-Pro-Gly-Val-Gly-Val-Pro-Gly-Gly, or VPGVGVPGG (SEQ ID NO: 12).
[071] Such structural units defined by SEQ ID NOS:1-12 may form structural repeat units, or may be used in combination to form an ELP component in accordance with the invention. In some embodiments, the ELP component is formed entirely (or almost entirely) of one or a combination of (e.g., 2, 3 or 4) structural units selected from SEQ ID NOS: 1-12. In other embodiments, at least 75%, or at least 80%, or at least 90% of the ELP component is formed from one or a combination of structural units selected from SEQ ID NOS: 1-12, and which may be present as repeating units.
[072] In certain embodiments, the ELP component(s) contain repeating units, including tandem repeating units, of the pentapeptide Val-Pro-Gly-X-Gly (SEQ ID NO: 3), where X is as defined above, and where the percentage of Val-Pro-Gly-X-Gly (SEQ ID NO: 3) pentapeptide units taken with respect to the entire ELP component (which may comprise structural units other than VPGXG (SEQ ID NO: 3)) is greater than about 75%, or greater than about 85%, or greater than about 95% of the ELP component. The ELP component may contain motifs having a 5 to 15-unit repeat (e.g. about 10-unit or about 12-unit repeat) of the pentapeptide of SEQ ID NO: 3, with the guest residue X varying among at least 2 or at least 3 of the structural units within each repeat. The guest residues may be independently selected, such as from the amino acids Val, Me, Leu, Ala, Gly, and Trp (and may be selected so as to retain a desired inverse phase transition property). Exemplary motifs include VPGXG (SEQ ID NO: 3), where the guest residues are Val (which may be present in from 40% to 60% of structural units), Gly (which may be present in 20% to 40% of structural units, and Ala (which may be present in 10% to 30% of structural units). The repeat motif itself may be repeated, for example, from about 5 to about 20 times, such as about 8 to 15 times (e.g., about 12 times), to create an exemplary ELP component. The ELP component as described in this paragraph may of course be constructed from any one of the structural units defined by SEQ ID NOS: 1-12, or a combination thereof. An exemplary ELP component is shown in Figure 1 fused to the C-terminus of VIP.
[073] In some embodiments, the ELP units may form a &tum structure that provides an elastin-like property (e.g., inverse phase transition). Exemplary peptide sequences suitable for creating a &turn structure are described in International Patent Publication No. WO 1996/032406, which is hereby incorporated by reference in its entirety. For example, the fourth residue (X) in the elastin pentapeptide sequence, VPGXG (SEQ ID NO: 3), can be altered without eliminating the formation of a D-turn.
[074] In certain embodiments, the ELP components include polymeric or oligomeric repeats of the pentapeptide VPGXG (SEQ ID NO: 3), where the guest residue X is any amino acid. X may be a naturally occurring or non-naturally occurring amino acid. In some embodiments, X is selected from alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, serine, threonine, tryptophan, tyrosine and valine. In some embodiments, X is a natural amino acid other than proline or cysteine.
[075] The guest residue X (e.g., with respect to SEQ ID NO: 3, or other ELP structural unit) may be a non-classical (non-genetically encoded) amino acid. Examples of non- classical amino acids include: D-isomers of the common amino acids, 2,4-diaminobutyric acid, I -amino isobutyric acid, A-aminobutyric acid, Abu, 2-amino butyric acid, Q-Abu, Γ -Ahx, 6-amino hexanoic acid, Aib, 2-amino isobutyric acid, 3-amino propionic acid, ornithine, norleucine, norvaline, hydroxyproline, sarcosine, citrulline, homocitrulline, cysteic acid, t- butylglycine, t-butylalanine, phenylglycine, cyclohexylalanine, Oalanine, fluoro-amino acids, designer amino acids such as &methyl amino acids, CI -methyl amino acids, l -methyl amino acids, and amino acid analogs in general.
[076] Selection of X may be independent in each ELP structural unit (e.g., for each structural unit defined herein having a guest residue X). For example, X may be independently selected for each structural unit as an amino acid having a positively charged side chain, an amino acid having a negatively charged side chain, or an amino acid having a neutral side chain, including in some embodiments, a hydrophobic side chain.
[077] In still other embodiments, the ELP component(s) may include polymeric or oligomeric repeats of the pentapeptides VPGXG (SEQ ID NO:3), IPGXG (SEQ ID NO:5) or LPGXG (SEQ ID NO:7), or a combination thereof, where X is as defined above.
[078] In each embodiment, the structural units, or in some cases polymeric or oligomeric repeats, of the ELP sequences may be separated by one or more amino acid residues that do not eliminate the overall effect of the molecule, that is, in imparting certain improvements to the therapeutic component as described herein. In certain embodiments,
such one or more amino acids also do not eliminate or substantially affect the phase transition properties of the ELP component (relative to the deletion of such one or more amino acids).
[079] The structure of the resulting ELP components may be described using the notation ELPk [XjYj-n], where k designates a particular ELP repeat unit, the bracketed capital letters are single letter amino acid codes and their corresponding subscripts designate the relative ratio of each guest residue X in the structural units (where applicable), and n describes the total length of the ELP in number of the structural repeats. For example, ELP1 [V5A2G3-IO] designates an ELP component containing 10 repeating units of the pentapeptide VPGXG (SEQ ID NO:3), where X is valine, alanine, and glycine at a relative ratio of 5:2:3; ELP1 [K1V7F1-4] designates an ELP component containing 4 repeating units of the pentapeptide VPGXG (SEQ ID NO:3), where X is lysine, valine, and phenylalanine at a relative ratio of 1 :2:1 ; ELP1 [K1V7F1-9] designates a polypeptide containing 9 repeating units of the pentapeptide VPGXG (SEQ ID NO:3), where X is lysine, valine, and phenylalanine at a relative ratio of 1 :7:1 ; ELP1 [V1A8G7-10] designates an ELP component containing 10 repeating units of the pentapeptide VPGXG (SEQ ID NO:3), where X is valine, alanine, and glycine at a relative ratio of 1 :8:7; ELP1 [V-5] designates a polypeptide containing 5 repeating units of the pentapeptide VPGXG (SEQ ID NO:3), where X is exclusively valine; ELP1 [V-20] designates a polypeptide containing 20 repeating units of the pentapeptide VPGXG (SEQ ID NO:3), where X is exclusively valine; ELP2 [5] designates a polypeptide containing 5 repeating units of the pentapeptide AVGVP (SEQ ID NO:4); ELP3 [V-5] designates a polypeptide containing 5 repeating units of the pentapeptide IPGXG (SEQ ID NO:5), where X is exclusively valine; ELP4 [V-5] designates a polypeptide containing 5 repeating units of the pentapeptide LPGXG (SEQ ID NO:7), where X is exclusively valine. Such ELP components as described in this paragraph may be used in connection with the present invention to increase the therapeutic properties of the therapeutic component.
[080] Further, the Tt is a function of the hydrophobicity of the guest residue. Thus, by varying the identity of the guest residue(s) and their mole fraction(s), ELPs can be synthesized that exhibit an inverse transition over a 0-100°C range. Thus, the Tt at a given ELP length may be decreased by incorporating a larger fraction of hydrophobic guest residues in the ELP sequence. Examples of suitable hydrophobic guest residues include valine, leucine, isoleucine, phenylalanine, tryptophan and methionine. Tyrosine, which is moderately hydrophobic, may also be used. Conversely, the Tt may be increased by incorporating residues, such as those selected from the group consisting of: glutamic acid,
cysteine, lysine, aspartate, alanine, asparagine, serine, threonine, glycine, arginine, and glutamine; preferably selected from alanine, serine, threonine and glutamic acid.
[081] The ELP component in some embodiments is selected or designed to provide a Tt (under physiological conditions) ranging from about 10°C to about 80°C, such as from about 35°C to about 60°C, or from about 38°C to about 45°C. In some embodiments, the Tt is greater than about 40°C or greater than about 42°C, or greater than about 45°C, or greater than about 50°C. The transition temperature, in some embodiments, is above the body temperature of the subject or patient (e.g., > 37°C) thereby remaining soluble in vivo, or in other embodiments, the Tt is below the body temperature (e.g., < 37°C) to provide alternative advantages, such as in vivo formation of a drug depot for sustained release of the therapeutic agent. See, for example, US Patent Publication No. US 2007/0009602, which is hereby incorporated by reference in its entirety.
[082] The Tt of the ELP component can be modified by varying ELP chain length, as the Tt generally increases with decreasing molecular weight (MW). For polypeptides having a molecular weight of > 100,000, the hydrophobicity scale developed by Urry et al. (International Patent Publication No. WO 1996/032406, which is hereby incorporated by reference in its entirety) provides one means for predicting the approximate Tt of a specific ELP sequence. However, in some embodiments, ELP component length can be kept relatively small, while maintaining a target Tt, by incorporating a larger fraction of hydrophobic guest residues (e.g., amino acid residues having hydrophobic side chains) in the ELP sequence. For polypeptides having a molecular weight of < 00,000, the Tt may be predicted or determined by the following quadratic function: Tt = M0 + M 1X + M2X2 where X is the MW of the fusion protein, and M0 = 1 16.21 ; M1 = -1.7499; M2 = 0.010349.
[083] While the Tt of the ELP component, and therefore of the ELP component coupled to a therapeutic component, is affected by the identity and hydrophobicity of the guest residue, X, additional properties of the molecule may also be affected. Such properties include, but are not limited to solubility, bioavailability, persistence, half-life, potency and safety of the molecule.
[084] In the Examples section below, it is seen that the ELP-coupled VIP agent retains a significant amount of the native VIP's biological activity, relative to unfused forms of VIP. Additionally, it is shown that ELPs exhibit long half-lives. Correspondingly, ELPs can be used in accordance with the invention to substantially increase (e.g. by greater than 10%, 20%, 30%, 50%, 100%, 200% or more, in specific embodiments) the half-life of VIP, as conjugated with an ELP, in comparison to the half-life of the free (unconjugated) form of the
therapeutic agent. The modified VIP having extended circulatory half-life may be administered from 1 to about 10 times per week, such as from 1 to about 5 times per week, or 1 to about 3 times per week. The modified VIP or pharmaceutical composition comprising the same may be administered about once daily, or about every other day, or about every third day, or about once a week (i.e. once weekly dosing).
[085] A recombinantly-produced VIP fusion protein, in accordance with certain embodiments of the invention, includes the fusion component (e.g., ELP) and a VIP or an analog of VIP associated with one another by genetic fusion. For example, the fusion protein may be generated by translation of a polynucleotide encoding VIP or an analog of VIP cloned in-frame with the ELP component.
[086] In certain embodiments, the ELP component and VIP or an analog of VIP can be fused using a linker peptide of various lengths to provide greater physical separation and allow more spatial mobility between the fused portions, and thus maximize the accessibility of VIP or an analog of VIP, for instance, for binding to its cognate receptor. The linker peptide may consist of amino acids that are flexible or more rigid. For example, a flexible linker may include amino acids having relatively small side chains, and which may be hydrophilic. Without limitation, the flexible linker may comprise glycine and/or serine residues. More rigid linkers may contain, for example, more sterically hindering amino acid side chains, such as (without limitation) tyrosine or histidine. The linker may be less than about 50, 40, 30, 20, 10, or 5 amino acid residues. The linker can be covalently linked to and between VIP or an analog of VIP and an ELP component, for example, via recombinant fusion.
[087] The linker or peptide spacer may be protease-cleavable or non-cleavable. By way of example, cleavable peptide spacers include, without limitation, a peptide sequence recognized by proteases (in vitro or in vivo) of varying type, such as Tev, thrombin, factor Xa, plasmin (blood proteases), metalloproteases, cathepsins, and proteases found in other corporeal compartments. In some embodiments employing cleavable linkers, the fusion protein may be inactive, less active, or less potent as a fusion, which is then activated upon cleavage of the spacer in vivo. Alternatively, where the therapeutic agent is sufficiently active as a fusion, a non-cleavable spacer may be employed. The non-cleavable spacer may be of any suitable type, including, for example, non-cleavable spacer moieties having the formula [(Gly)n-Ser]m, where n is from 1 to 4, inclusive, and m is from 1 to 4, inclusive. Alternatively, a short ELP sequence different than the backbone ELP could be employed instead of a linker or spacer, while accomplishing the necessary effect.
[088] In still other embodiments, the therapeutic agent is a recombinant fusion having a therapeutic component flanked on each terminus by an ELP component. At least one of said ELP components may be attached via a cleavable spacer, such that the therapeutic component is inactive, but activated in vivo by proteolytic removal of a single ELP component. The resulting single ELP fusion being active, and having an enhanced half-life (or other property described herein) in vivo.
[089] In other embodiments, the present invention provides chemical conjugates of a VIP or an analog of VIP and the ELP component. The conjugates can be made by chemically coupling an ELP component to VIP or an analog of VIP by any number of methods well known in the art (See e.g., Nilsson ef a/., 2005, Ann Rev Biophys Bio Structure 34: 91-1 18). In some embodiments, the chemical conjugate can be formed by covalently linking VIP or an analog of VIP to the ELP component, directly or through a short or long linker moiety, through one or more functional groups on the therapeutic proteinacious component, e.g., amine, carboxyl, phenyl, thiol or hydroxyl groups, to form a covalent conjugate. Various conventional linkers can be used, e.g., diisocyanates, diisothiocyanates, carbodiimides, bis (hydroxysuccinimide) esters, maleimide- hydroxysuccinimide esters, glutaraldehyde and the like.
[090] Non-peptide chemical spacers can additionally be of any suitable type, including for example, by functional linkers described in Bioconjugate Techniques, Greg T. Hermanson, published by Academic Press, Inc., 1995, and those specified in the Cross- Linking Reagents Technical Handbook, available from Pierce Biotechnology, Inc. (Rockford, Illinois), the disclosures of which are hereby incorporated by reference, in their respective entireties. Illustrative chemical spacers include homobifunctional linkers that can attach to amine groups of Lys, as well as heterobifunctional linkers that can attach to Cys at one terminus, and to Lys at the other terminus.
[091] In certain embodiments, relatively small ELP components (e.g., ELP components of less than about 30 kDa, 25 kDa, 20 kDa, 15 kDa, or 10 kDa), that do not transition at room temperature (or human body temperature, e.g., Tt >37°C), are chemically coupled or crosslinked. For example, two relatively small ELP components, having the same or different properties, may be chemically coupled. Such coupling, in some embodiments, may take place in vivo, by the addition of a single cysteine residue at or around the C-terminus of the ELP. Such ELP components may each be fused to one or more therapeutic components, so as to increase activity or avidity at the target.
[092] The present invention further provides pharmaceutical compositions comprising an effective amount of a modified VIP having a binding preference for VPAC2 and at least one anti-hypertensive drug, together with a pharmaceutically acceptable carrier, diluent, or excipient. Such pharmaceutical compositions are effective for treating or ameliorating hypertension, as described herein.
[093] It is contemplated that each of the therapeutic agents may be administered per se as well as in various forms including pharmaceutically acceptable esters, salts, and other physiologically functional derivatives thereof. It is further contemplated that the therapeutic agents may be formulated solely, or together with other therapeutic agents. For example, the modified VIP having a binding preference for VPAC2 and the one or more antihypertensive drugs may be administered as a single formulation or as separation formulations.
[094] The formulations of the therapeutic agent include those suitable for parenteral as well as non-parenteral administration. Exemplary administration modalities include oral, buccal, topical, nasal, pulmonary, subcutaneous, intramuscular, and intravenous, among others. Formulations suitable for parenteral administration are preferred.
[095] The formulations comprising the therapeutic agent of the present invention may conveniently be presented in unit dosage forms and may be prepared by any of the methods well known in the art of pharmacy. Such methods generally include the step of bringing the therapeutic agents into association with a carrier which constitutes one or more accessory ingredients. Typically, the formulations are prepared by uniformly and intimately bringing the therapeutic agent into association with a liquid carrier, a finely divided solid carrier, or both, and then, if necessary, shaping the product into dosage forms of the desired formulation.
[096] Formulations suitable for parenteral administration conveniently comprise a sterile aqueous preparation of the therapeutic agent, which preferably is isotonic with the blood of the recipient (e.g., physiological saline solution). Such formulations may include suspending agents and thickening agents or other microparticulate systems which are designed to target the therapeutic agent to the circulation or one or more organs. The formulations may be presented in unit-dose or multi-dose form.
[097] In addition to the aforementioned ingredients, the formulations of this invention may further include one or more accessory ingredient(s) selected from diluents, buffers,
flavoring agents, disintegrants, surface active agents, thickeners, lubricants, preservatives (including antioxidants), and the like.
[098] While one of skill in the art can determine the desirable dose in each case (including a unit dose for depot administration), a suitable dose of the therapeutic agent having the amino acid sequence of SEQ ID NO:14 be in a range of about 1 microgram (qg) to about 100 milligrams (mg) per kilogram body weight of the recipient, or in a range of about 10 qg to about 50 mg per kilogram body weight, or in a range of about 10 qg to about 10 mg per kilogram body weight. The desired dose may be presented as one dose or two or more sub-doses administered at appropriate intervals throughout the dosing period (e.g., one week, two weeks, etc). These sub-doses can be administered in unit dosage forms, for example, containing from about 10 qg to about 500 mg, or from about 50 qg to about 200 mg, or from about 50 qg to about 100 mg of active ingredient per unit dosage form. Alternatively, if the condition of the recipient so requires, the doses may be administered as a continuous infusion.
[099] The mode of administration and dosage forms will of course affect the therapeutic amount of the peptide active therapeutic agent that is desirable and efficacious for a given treatment application. For example, orally administered dosages can be at least twice, e.g., 2-10 times, the dosage levels used in parenteral administration methods. Depot formulations will also allow for significantly more therapeutic agent to be delivered, such that the agent will have a sustained release over time.
[0100] In accordance with certain embodiments of the invention, the VIP may be administered from 1 to about 10 times per week, such as from 1 to about 5 times per week, or 1 to about 3 times per week. The modified VIP or pharmaceutical composition comprising the same may be administered about once daily, or about every other day, or about every third day, or about once a week.
[0101] In certain embodiments, the modified VIP is administered parenterally, such as by subcutaneous or intramuscular injection. The administration may be a unit dose of the modified VIP as described herein.
[0102] The modified VIP, when administered parenterally, may be administered once per day, or once or twice per week, or from once to five times per month. In these embodiments, the modified VIP may be administered as a soluble fusion peptide, that persists in the circulation, as described herein, to provide sustained activity with relatively
infrequent administration. The modified VIP may be administered as a drug depot, as also described herein, to provide a sustained release of fusion peptide into the circulation over time. See US Patent Applicaton Publication No. 2007/0009602, which is hereby incorporated by reference.
[0103] The present invention provides methods of treating and/or ameliorating hypertension in a patient. In certain aspects, the invention is for use in combination therapy, whereby a modified vasoactive intestinal peptide having a binding preference for VPAC2 is administered to a patient undergoing therapy with one or more anti-hypertensive drugs such as an angiotensin converting enzyme (ACE) inhibitor, a Dl receptor antagonist, and/or a calcium channel blocker.
[0104] Co-administration of the modified VIP and the one or more anti-hypertensive drugs can be by concomitant administration of a single formulation or of separate formulations, e.g., a modified VIP formulation and a formulation of one or more antihypertensive drugs. Co-administration does not require the therapeutic agents to be administered simultaneously. Administration of separate formulations is considered "concomitant" if the timing of their administration is such that the pharmacological activities of the modified VIP and the one or more anti-hypertensive drugs overlap in time, thereby exerting a combined anti-hypertensive effect in the patient. Accordingly, the modified VIP with a binding preference for VPAC2 may be administered prior to, at the same time, or after the administration of the one or more anti-hypertensive drugs. Co-administration also does not require the therapeutic agents to be administered by the same route of administration. Rather, each therapeutic agent can be effected by any appropriate route. For example, the modified VIP may be administered subcutaneously while the calcium channel blocker may be administered orally.
[0105] The co-administration of the modified VIP with a binding preference for VPAC2 and the one or more anti-hypertensive drugs provides beneficial effects derived from the co- action of these therapeutic agents. It is contemplated that a VIP having a binding preference for VPAC2 can provide long-acting blood pressure control synergistically with concomitant anti-hypertensive therapies. Accordingly, the invention provides specific advantages such as sustained blood pressure control, enhanced efficacy of treatment, and/or reduced side effects.
[0106] The present invention is further illustrated by the following examples that should not be construed as limiting. The contents of all references, patents, and published patent
applications cited throughout this application, as well as the Figures, are incorporated herein by reference in their entirety for all purposes.
EXAMPLES
Example 1
Cloning of VIP-ELP Constructs
[0107] The DNA sequence for the VIP peptide was as described in Simoncsits ef al. (Eur. J. Biochem. 1988, 178(2):343-350, which is herein incorporated by reference in its entirety for all purposes), except that residue 17 was the native methionine and did not have either of the described C-terminal extensions.
[0108] Two initial variants were made, one with a methionine at the N-terminus, due to the required ATG start codon, (PB1046) and one with the tripeptide MAA at the N-terminus (PB1047). The methionine on PB1046 would normally be removed by methionine aminopeptidase (MA) but as histidine is the second residue and one of the least favored amino acids at this position for MA, the methionine is not removed. The methionine on PB1047 was removed to leave AA, which can then be removed in vitro or in vivo by DPPIV to give the histidine as the N-terminal residue. The VIP DNA sequence was cloned into vector pPB1031 (see Figure 3) carrying the ELP1-120 DNA sequence to give an expression cassette under the control of the T7 promoter.
[0109] The synthetic oligonucleotides P0045, P0048, P0064 and P0065 were annealed together, digested with the restriction enzyme Xbal and ligated into the plasmid pPB1031 which had been digested with the restriction enzymes Xbal/Kpnl to give expression plasmid pPB1046 (see Figure 4).
[0110] The synthetic oligonucleotides P0066, P0064, P0067 and P0065 were annealed together, digested with the restriction enzyme Xbal and ligated into the plasmid pPB1031 which had been digested with the restriction enzymes Xbal/Kpnl to give expression plasmid pPB1047 (see Figure 5).
Example 2
Activity of Modified VIP-ELP Fusion Protein in vitro
[01 1] To measure the in vitro biological activity and potency of VIP or VIP-ELP fusion proteins, a cell-based bioassay was used. The assay measures the increase in intracellular cyclic adenosine monophosphate (cAMP) concentration in response to treatment with VIP or VIP-ELP fusion proteins in Chinese Hamster Ovary (CHO) cells that have been engineered
to express either the human Vasoactive Intestinal Peptide Receptor 2 (VPAC2) or the human Vasoactive Intestinal Peptide Receptor 1 (VPAC1 ). Both VIP and VIP-ELP fusion proteins can stimulate production of cAMP in these cells, indicating that the fusion proteins retain the ability to bind and activate the receptor. Since the amount of cAMP accumulation in cells after receptor-mediated ligand binding and activation is directly proportional to the amount of intact peptide or fusion protein present, the assay can be used to determine bioactivity and relative potency.
[0112] In this example, the activity of VIP-ELP fusion proteins PB1046 and PB1047 was tested. Construct PB1046 contains VIP with a Met at the N-terminus and construct PB1047 contains VIP with Ala-Ala at its N-terminus. Both constructs have ELP{1-120) at their C- terminus. In the first experiment, the activity of the constructs was tested using CHO cells expressing the VIP receptor VPAC2. After 30 minute incubations of various concentrations of the fusion proteins with the cell, the cells were lysed and the amount of cAMP produced was measured using a commercial kit. PB1047 was DPP-IV treated prior to the addition to the cells. Figure 6 shows the result. As shown, modified VIP fusion protein PB1046 is somewhat more active than native VIP protein, while PB1047 is less active.
The activity of PB1046 and PB1047 was also tested using CHO cells expressing the VIP receptor VPAC1. After 30 minute incubations of various concentrations of the fusion proteins with CHO cells, cells were lysed and the amount of cAMP produced was measured using a commercial kit. PB1047 was DPP-IV treated prior to the addition to the cells. Figure 7 shows the result. This time, modified VIP fusion protein PB1046 is much less active than native VIP protein, while the relative activity of PB1047 against native VIP is about the same as it was in the test for VPAC2 receptor. These results suggest that PB1046 selectively activates VPAC2 receptor over VPAC1 receptor.
Example 3
Blood pressure effect of VIP-ELP Fusion Protein
[0113] The activity of the modified VIP-ELP fusion protein PB1047 was also tested in vivo. Specifically, effects of VIP-ELP fusion protein on blood pressure were tested. Spontaneously hypertensive rats were treated subcutaneous with PB1047 (10 mg/kg) or buffer control and their blood pressures were measured at several points after administration of the fusion protein. Five animals were used for each group and the graphs show the average and the standard deviation. PB1047 significantly reduced systolic and diastolic blood pressure in these animals for at least 12 hours post administration (see Figure 8),
indicating that the VIP-ELP fusion protein is active, and can be potentially used as pharmaceuticals in treating VIP-related diseases.
Example 4
Cloning, Expression, and Analysis of an Additional VIP-ELP Fusion Protein, PB1120
[0114] The VIP DNA sequence was cloned into vector pPB1 120 (see Figure 9) carrying the ELP1 -120 DNA sequence to give an expression cassette under the control of the T7 promoter. Next, the E. coli production strain BLR was transformed with the pPB1 120 plasmid and grown in rich medium as described above. Samples of the resulting VIP-ELP1 - 120 fusion peptide, PB1 120, were purified and analyzed via SDS-PAGE.
[0115] The activity of the PB1 120 fusion peptide was tested in vitro. The activity was tested using an assay utilizing CHO cells expressing VIP receptor (VPAC1 ) as described above in Example 3. As Figure 10 demonstrates, PB1120 was approximately 1.4 fold less active than the native VIP peptide on the VPAC1 receptor. By comparison, the construct PB1046 which contains an N-terminal methionine residue was approximately 1 1-fold less active than the native VIP peptide. Over the course of multiple experiments, PB1 120 was anywhere from 1.4- to 6-fold less active than the native VIP peptide on the VPAC1 receptor.
[0116] Figure 11 illustrates the activity of PB1 120 for the VPAC2 receptor. Like the results seen for the VPAC1 receptor, PB1 120 show slightly less activity (~1.5 fold less) than the native VIP peptide for VPAC2. However, in contrast to the results seen with VPAC1 , PB1046 was equipotent for VPAC2 as compared to the native peptide. Over the course of multiple experiments, PB1 120 was anywhere from 1.5- to 7-fold less active than the native VIP peptide on the VPAC2 receptor.
Example 5
Pharmacokinetic Profile of Modified VIP-ELP Fusion Protein PB1120
[0117] In addition to the biological potency assays described above, the pharmacokinetic profile of the VIP-ELP fusion protein PB1 120 was also examined. Monkeys were given single subcutaneous (SC) injections (dosed at 3 mg/kg) of PB1 120 and plasma drug concentrations were measured daily over the course of one week. Three animals were used and the graphs show the average and the standard deviation. More than half of the initial dose of PB1 120 remained in the circulation to day 4 (see Figures 12A and 12B, which illustrate the mean plasma concentrations of PB1 120 after SC administration using linear and semi-logarithmic axes, respectively).
[0118] Based upon this data, there appears to be a prolonged absorption phase after subcutaneous administration of PB1 120, consistent with slow absorption from the site of administration. The apparent elimination half-life (t½), based on the decay of plasma concentrations, ranged from 9.9 to 45.8 h and likely reflects the slow absorption rather than true elimination. These data indicate that the VIP-ELP fusion protein has a dramatically extended half-life in comparison to native VIP and can potentially be administered at extended intervals (e.g. may be administered about once daily, about every other day, about every third day, or about once weekly).
Example 6
Effects of Modified VIP-ELP Fusion Protein PB1120 on Blood Pressure
[0119] To measure the effects of the modified VIP-ELP fusion protein PB1 120 on systolic, diastolic, and mean arterial blood pressure, rats were given single, subcutaneous injections of 0.1 mg/kg, 1 mg/kg, or 5 mg/kg of PB1120 and evaluated over 3-hr intervals. Figures 13A, 13B, and 13C show the average change in systolic, diastolic, and mean arterial pressure, respectively. Figure 13D shows the average heart rate over 3 hr intervals following administration of PB1 120. As Figures 13A-C demonstrate, rats injected with either 1 mg/kg or 5 mg/kg of PB1 120 showed significant reductions in systolic, diastolic, and mean arterial pressure 9 hrs post-injection, indicating that VIP-ELP fusion protein PB1 120 can potentially be administered for the purpose of treating or preventing hypertension in afflicted individuals.
Example 7
Blood Pressure Control With VPAC2-Selective VIP is Independent of U-AR Function
[0120] The natural vasoactive intestinal peptide (VIP) triggers potent vasodilatation by activating the G-protein-coupled VPAC1 and VPAC2 receptors; however, VIP's clinical utility is limited due to its short half-life and VPAC1 -mediated side-effects. Here, the effects of PB 1046 (Vasomera™) when given as a single-dose SQ bolus to conscious spontaneously hypertensive rats (SHR) was tested.
[0121] SHR rats (351 ± 4 g, n = 8) were instrumented for telemetric blood pressure and ECG monitoring. Via a Latin-Square design, the effects of Vasomera (1 , 3, and 9 mg/kg SQ) as well as of vehicle (VEH, SQ) were evaluated. Finally, Vasomera™ (9 mg/kg SQ) was assayed during concomitant ^adrenergic receptor blockade (BB, atenolol 20 mg/kg/day PO). Changes in mean arterial pressure (MAP) and heart rate (HR) were measured.
[0122] Vasomera™ induced dose-dependent decreases in blood pressure that were sustained for up to 12 hours post-dosing (see Figure 14A). For instance, at 9 mg/kg (177 nmol/kg), Vasomera™ lowered MAP by 16 ± 3 % (154 ± 5 mmHg vs. 184 ± 6 in VEH @+6hr, P < 0.05). Concomitantly, Vasomera™ triggered moderate cardio-acceleration (370 ± 15 bpm at 9 mg/kg vs. 322 ± 10 bpm in VEH @+2hr, P < 0.05). Notably, ^adrenergic receptor blockade blunted Vasomera™'s chronotropic effects (308 ± 3 bpm @ +2hr) while preserving/enhancing vaso-relaxation (MAP: 131 ± 3 mmHg @ +6hr) (see Figures 14B and 13C). No adverse clinical effects were noted.
[0123] These data suggest that Vasomera™ can provide long-acting blood pressure control synergistically with concomitant therapies (such as D-adrenergic receptor blockade) and may represent a novel adjunct therapeutic agent for resistant/uncontrolled hypertensive patients.
Example 8
Blood Pressure Control With VPAC2-Selective VIP in Conjunction With Antihypertensives
[0124] The hemodynamic effects of Vasomera™ when given as a single-dose SQ bolus to conscious spontaneously hypertensive rats (SHR) pretreated with three common antihypertensives were tested.
[0125] SHR rats (351 ± 4 g, n = 8) were instrumented for telemetric BP and ECG monitoring. First, both Vasomera™ (9 mg [177 nmol] /kg, SQ) and placebo (VEH) were assayed in untreated animals. Then, the effects of Vasomera™ were tested during concomitant oral Oadrenergic receptor blockade (+BB, atenolol 20 mg/kg/day), calcium- channel blockade (+CCB, amlodipine 5 mg/kg/day) and ACE-inhibition (+ACE, ramipril 1 mg/kg/day). Mean arterial pressure (MAP) and heart rate (HR) were measured/averaged over 24 hours both pre- and post-dosing.
[0126] Vasomera™ induced potent decreases in blood pressure that were sustained for up to 12 hours post-dosing (see Figure 15A). On average, Vasomera™ lowered MAP by 9 ± 1 % (188 ± 6 to 171 ± 5 mmHg, P < 0.05). Vasomera™'s vaso-relaxation was preserved/enhanced in rats pre-treated with either atenolol (-14 ± 1 %, P < 0.05), amlodipine (-13 ± 2%, P < 0.05), and/or ramipril (-9 ± 2%, P < 0.05) (see Figure 15B). Vasomera™ triggered moderate cardio-acceleration in untreated rats (+8 ± 1 %, 355 ± 6 to 384 ± 8 bpm, P < 0.05); such chronotropy was blunted under D-adrenergic receptor blockade (+6 ± 1 %, 278 ± 2 to 294 ± 2 bpm), but was unaffected by amlodipine or ramipril (see Figure 15C). In all cases, heart rates were lower than in controls, and no adverse clinical effects were noted.
[0127] These results demonstrate that co-administration of Vasomera™ with concomitant anti-hypertensive therapies (e.g., ^adrenergic receptor blockade) can provide enhanced long-acting blood pressure control as well as reduced side effects.
[0128] Unless defined otherwise, all technical and scientific terms herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials, similar or equivalent to those described herein, can be used in the practice or testing of the present invention, the preferred methods and materials are described herein. All publications, patents, and patent publications cited are incorporated by reference herein in their entirety for all purposes.
[0129] The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention.
[0130] While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains and as may be applied to the essential features hereinbefore set forth and as follows in the scope of the appended claims.
Claims
1. A method for treating hypertension in a patient, comprising administering to the patient: a vasoactive intestinal peptide having a binding preference for the Vasoactive Intestinal Peptide Receptor 2 (VPAC2), and at least one anti-hypertensive drug selected from a Π1 receptor antagonist, an ACE inhibitor, and a calcium channel blocker.
2. The method of claim 1 , wherein said hypertension is selected from pulmonary hypertension, uncontrolled essential hypertension, and resistant hypertension.
3. The method of claim 1 or 2, wherein said vasoactive intestinal peptide induces vasorelaxation.
4. The method of any one of claims 1 -3, wherein said vasoactive intestinal peptide induces decrease of at least one of systolic pressure, diastolic pressure, and mean arterial pressure.
5. The method of any one of claims 1 -4, wherein said vasoactive intestinal peptide comprises an N-terminal moiety so as to provide binding preference for VPAC2.
6. The method of claim 5, wherein said vasoactive intestinal peptide comprises the amino acid sequence MHSDAVFTDNYTRLRKOMAVKKYLNSILN (SEQ ID NO:13).
7. The method claim 6, wherein said vasoactive intestinal peptide optionally comprises 1 to 5 amino acid insertions, deletions, and/or substitutions, collectively, with respect to SEQ ID NO:13.
8. The method of any one of claims 1 -7, wherein said vasoactive intestinal peptide comprises a heterologous fusion partner.
9. The method of claim 8, wherein said heterologous fusion partner comprises at least one elastin-like peptide component.
10. The method of claim 9, wherein said elastin-like peptide component is constructed of one or more amino acid repeat units defined by SEQ ID NOS: 1 -12.
11. The method of claim 10, wherein said elastin-like peptide component comprises repeats of VPGXG (SEQ ID NO: 3), IPGXG (SEQ ID NO: 5), and/or LPGXG (SEQ ID NO: 7), wherein X is a genetically-encoded amino acid.
12. The method of claim 11 , wherein said elastin-like peptide component comprises VPGXG (SEQ ID NO: 3) repeats, wherein X is independently selected from V, A, and G, or is independently selected from K, V, and F.
13. The method of claim 12, wherein X is V, A, and G in a ratio of about V5, A2, and G3.
14. The method of claim 13, wherein said elastin-like peptide component comprises 60 repeating units of VPGXG (SEQ ID NO: 3).
15. The method of claim 13, wherein said elastin-like peptide component comprises 120 repeating units of VPGXG (SEQ ID NO: 3).
16. The method of any one of claims 1-15, wherein said heterologous fusion partner is at the carboxy-terminus.
17. The method of claim 16, wherein said vasoactive intestinal peptide has the amino acid sequence of SEQ ID NO: 14.
18. The method of any one of claims 1-17, wherein said Π1 receptor antagonist is Atenolol.
19. The method of any one of claims 1-17, wherein said ACE inhibitor is Ramipril.
20. The method of any one of claims 1-17, wherein said calcium channel blocker is Amlodipine.
21. The method of any one of claims 1-20, wherein said vasoactive intestinal peptide and said anti-hypertensive drug are administered separately.
22. The method of any one of claims 1 -21 , wherein said vasoactive intestinal peptide is administered parenterally.
23. The method of claim 22, wherein said vasoactive intestinal peptide is administered subcutaneously.
24. The method of any one of claims 1 -23, wherein said vasoactive intestinal peptide is administered about once per day.
25. The method of any one of claims 1 -23, wherein said vasoactive intestinal peptide is administered about once per week.
26. The method of any one of claims 1-25, wherein said vasoactive intestinal peptide has the amino acid sequence of SEQ ID NO:14 and is administered at a dose of about 1 microgram to about 100 milligrams per kilogram of body weight.
27. The method of claim 26, wherein said vasoactive intestinal peptide is administered at a dose of about 10 microgram to about 10 milligrams per kilogram of body weight.
28. The method of any one of claims 1-27, wherein the co-administration of said vasoactive intestinal peptide and said anti-hypertensive drug produces synergistic or additive therapeutic effects.
29. The method of any one of claims 1-28, wherein said patient is a human patient.
30. A pharmaceutical composition comprising a vasoactive intestinal peptide having a binding preference for the Vasoactive Intestinal Peptide Receptor 2, and at least one antihypertensive drug selected from a Ol receptor antagonist, an ACE inhibitor, and a calcium channel blocker.
31. The pharmaceutical composition of claim 30, wherein the composition is formulated for once per day dosing.
32. The pharmaceutical composition of claim 30, wherein the composition is formulated for once per week dosing.
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2873553A CA2873553C (en) | 2011-06-06 | 2012-06-06 | Use of modified vasoactive intestinal peptides in the treatment of hypertension |
EP12796397.3A EP2717902B1 (en) | 2011-06-06 | 2012-06-06 | Use of modified vasoactive intestinal peptides in the treatment of hypertension |
US14/124,612 US9561262B2 (en) | 2011-06-06 | 2012-06-06 | Use of modified vasoactive intestinal peptides in the treatment of hypertension |
ES12796397.3T ES2669190T3 (en) | 2011-06-06 | 2012-06-06 | Use of modified vasoactive intestinal peptides in the treatment of hypertension |
US15/276,151 US10940182B2 (en) | 2011-06-06 | 2016-09-26 | Use of modified vasoactive intestinal peptides in the treatment of hypertension |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161493845P | 2011-06-06 | 2011-06-06 | |
US61/493,845 | 2011-06-06 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/124,612 A-371-Of-International US9561262B2 (en) | 2011-06-06 | 2012-06-06 | Use of modified vasoactive intestinal peptides in the treatment of hypertension |
US15/276,151 Continuation US10940182B2 (en) | 2011-06-06 | 2016-09-26 | Use of modified vasoactive intestinal peptides in the treatment of hypertension |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012170524A1 true WO2012170524A1 (en) | 2012-12-13 |
Family
ID=47296410
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2012/041092 WO2012170524A1 (en) | 2011-06-06 | 2012-06-06 | Use of modified vasoactive intestinal peptides in the treatment of hypertension |
Country Status (6)
Country | Link |
---|---|
US (2) | US9561262B2 (en) |
EP (1) | EP2717902B1 (en) |
CA (1) | CA2873553C (en) |
ES (1) | ES2669190T3 (en) |
NO (1) | NO2822914T3 (en) |
WO (1) | WO2012170524A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014028776A1 (en) * | 2012-08-15 | 2014-02-20 | Zyngenia, Inc. | Monovalent and multivalent multispecific complexes and uses thereof |
US9700598B2 (en) | 2009-08-14 | 2017-07-11 | Phasebio Pharmaceuticals, Inc. | Modified vasoactive intestinal peptides |
WO2017152399A1 (en) * | 2016-03-09 | 2017-09-14 | 兰州大学 | Fusion protein of vasoactive intestinal peptide and preparation method and use thereof |
EP3256151A4 (en) * | 2015-02-09 | 2018-08-22 | Phasebio Pharmaceuticals, Inc. | Methods and compositions for treating muscle disease and disorders |
US10940182B2 (en) | 2011-06-06 | 2021-03-09 | Phasebio Pharmaceuticals, Inc. | Use of modified vasoactive intestinal peptides in the treatment of hypertension |
US11052132B2 (en) | 2014-05-08 | 2021-07-06 | Phasebio Pharmaceuticals, Inc. | Methods and compositions for treating cystic fibrosis |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130172274A1 (en) | 2005-12-20 | 2013-07-04 | Duke University | Methods and compositions for delivering active agents with enhanced pharmacological properties |
EP2307038A4 (en) | 2008-06-27 | 2013-03-27 | Univ Duke | Therapeutic agents comprising elastin-like peptides |
EP4295858A1 (en) * | 2011-08-24 | 2023-12-27 | ImmunoForge Co., Ltd. | Formulations of active agents for sustained release |
BR112021022170A2 (en) * | 2019-05-07 | 2021-12-21 | Advita Lifescience Gmbh | Vasoactive intestinal peptide (VIP) for use in the treatment of drug-induced pneumonitis |
Citations (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4132746A (en) | 1976-07-09 | 1979-01-02 | University Of Alabama, Birmingham Medical & Education Foundation | Synthetic elastomeric insoluble cross-linked polypentapeptide |
US4187852A (en) | 1976-07-09 | 1980-02-12 | The University Of Alabama | Synthetic elastomeric insoluble cross-linked polypentapeptide |
US4474851A (en) | 1981-10-02 | 1984-10-02 | The University Of Alabama In Birmingham | Elastomeric composite material comprising a polypeptide |
US4500700A (en) | 1981-10-02 | 1985-02-19 | The Board Of Trustees Of The University Of Alabama For The University Of Alabama In Birmingham | Elastomeric composite material comprising a polypentapeptide having an amino acid of opposite chirality in position three |
US4589882A (en) | 1983-09-19 | 1986-05-20 | Urry Dan W | Enzymatically crosslinked bioelastomers |
US4605641A (en) | 1984-10-09 | 1986-08-12 | Hoffmann-La Roche Inc. | Synthetic vasoactive intestinal peptide analogs |
US4734400A (en) | 1984-10-09 | 1988-03-29 | Hoffmann-La Roche Inc. | Synthetic vasoactive intestinal peptide analogs |
US4835252A (en) | 1987-02-26 | 1989-05-30 | The Salk Institute Biotechnology/Industrial Associates, Inc. | Vasoactive intestinal peptide analogs |
US4870055A (en) | 1986-04-17 | 1989-09-26 | University Of Alabama At Birmingham | Segmented polypeptide bioelastomers to modulate elastic modulus |
US4939224A (en) | 1987-02-26 | 1990-07-03 | The Salk Institute Biotechnology/Industrial Associates, Inc. | Vasoactive intestinal peptide analogs |
US5141924A (en) | 1989-06-30 | 1992-08-25 | Hoffmann-La Roche, Inc. | Synthetic vasoactive intestinal peptide analogs |
US5520672A (en) | 1991-04-19 | 1996-05-28 | Urry; Dan W. | Superabsorbent materials and uses thereof |
WO1996032406A1 (en) | 1995-04-14 | 1996-10-17 | Bioelastics Research Ltd. | A simple method for the purification of a bioelastic polymer |
US5677419A (en) | 1991-10-11 | 1997-10-14 | Hoffmann-La Roche Inc. | Cyclic vasoactive peptide analogs |
US5766883A (en) | 1989-04-29 | 1998-06-16 | Delta Biotechnology Limited | Polypeptides |
US5972883A (en) | 1993-03-16 | 1999-10-26 | Yeda Research And Development Co. Ltd. | Method for the treatment of neurodegenerative diseases by administering VIP, an analogue, fragment or a conjugate thereof |
US6063061A (en) | 1996-08-27 | 2000-05-16 | Fusion Medical Technologies, Inc. | Fragmented polymeric compositions and methods for their use |
US6080837A (en) | 1996-02-09 | 2000-06-27 | Hoffmann-La Roche Inc. | Synthesis of VIP analog |
US6489297B1 (en) | 2000-02-18 | 2002-12-03 | Dabur Research Foundation | Vasoactive intestinal peptide analogs |
US6608174B1 (en) | 2000-02-18 | 2003-08-19 | Dabur Research Foundation | Radiolabeled vasoactive intestinal peptide analogs for diagnosis and radiotherapy |
US6699294B2 (en) | 1998-02-27 | 2004-03-02 | Bioelastics Research, Ltd. | Injectable implants for tissue augmentation and restoration |
US6753311B2 (en) | 2000-06-23 | 2004-06-22 | Drexel University | Collagen or collagen-like peptide containing polymeric matrices |
US20070009602A1 (en) | 2005-06-24 | 2007-01-11 | Setton Lori A | Direct drug delivery system based on thermally responsive biopolymers |
US7176278B2 (en) | 2001-08-30 | 2007-02-13 | Biorexis Technology, Inc. | Modified transferrin fusion proteins |
US7238667B2 (en) | 2001-12-21 | 2007-07-03 | Human Genome Sciences, Inc. | Albumin fusion proteins |
WO2008030968A2 (en) | 2006-09-06 | 2008-03-13 | Phase Bioscience, Inc. | Fusion peptide therapeutic compositions |
US20080221041A1 (en) * | 2000-11-28 | 2008-09-11 | Lutz-Henning Block | Compounds with the biological activity of vasoactive intestinal peptide for the treatment of pulmonary and arteriolar hypertension |
US20080261863A1 (en) * | 2004-06-12 | 2008-10-23 | Bayer Pharmaceuticals Corp | Pegylation of Vasoactive Intestinal Peptide (Vip) / Pituitary Adenylate Cyclase Activating Peptide (Pacap) Receptor 2 (Vpac2) Agonists and Methods of Use |
WO2011020091A1 (en) | 2009-08-14 | 2011-02-17 | Phasebio Pharmaceuticals, Inc. | Modified vasoactive intestinal peptides |
Family Cites Families (118)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4752638A (en) | 1983-11-10 | 1988-06-21 | Genetic Systems Corporation | Synthesis and use of polymers containing integral binding-pair members |
US4749647A (en) | 1984-06-22 | 1988-06-07 | Genetic Systems Corporation | Polymerization-induced separation assay using recognition pairs |
US4783523A (en) | 1986-08-27 | 1988-11-08 | Urry Dan W | Temperature correlated force and structure development of elastin polytetrapeptides and polypentapeptides |
US7138486B2 (en) | 1986-05-05 | 2006-11-21 | The General Hospital Corporation | Insulinotropic hormone derivatives and uses thereof |
US4898926A (en) | 1987-06-15 | 1990-02-06 | The University Of Alabama At Birmingham/Research Foundation | Bioelastomer containing tetra/penta-peptide units |
US6184348B1 (en) | 1986-11-04 | 2001-02-06 | Protein Polymer Technologies | Functional recombinantly prepared synthetic protein polymer |
US5773249A (en) | 1986-11-04 | 1998-06-30 | Protein Polymer Technologies, Inc. | High molecular weight collagen-like protein polymers |
US5770697A (en) | 1986-11-04 | 1998-06-23 | Protein Polymer Technologies, Inc. | Peptides comprising repetitive units of amino acids and DNA sequences encoding the same |
US6018030A (en) | 1986-11-04 | 2000-01-25 | Protein Polymer Technologies, Inc. | Peptides comprising repetitive units of amino acids and DNA sequences encoding the same |
US5243038A (en) | 1986-11-04 | 1993-09-07 | Protein Polymer Technologies, Inc. | Construction of synthetic DNA and its use in large polypeptide synthesis |
US5514581A (en) | 1986-11-04 | 1996-05-07 | Protein Polymer Technologies, Inc. | Functional recombinantly prepared synthetic protein polymer |
US5830713A (en) | 1986-11-04 | 1998-11-03 | Protein Polymer Technologies, Inc. | Methods for preparing synthetic repetitive DNA |
US5496712A (en) | 1990-11-06 | 1996-03-05 | Protein Polymer | High molecular weight collagen-like protein polymers |
US5641648A (en) | 1986-11-04 | 1997-06-24 | Protein Polymer Technologies, Inc. | Methods for preparing synthetic repetitive DNA |
US5606019A (en) | 1987-10-29 | 1997-02-25 | Protien Polymer Technologies, Inc. | Synthetic protein as implantables |
IL87055A (en) | 1988-07-08 | 1994-06-24 | Illana Gozes | Conjugates of vasoactive intestinal peptide (vip) and of fragments thereof and pharmaceutical compositions comprising them |
US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
US5234907A (en) | 1989-06-30 | 1993-08-10 | Hoffmann-La Roche Inc. | Synthetic vasoactive intestinal peptide analogs |
US5236904A (en) | 1989-09-18 | 1993-08-17 | Senetek, Plc | Erection-inducing methods and compositions |
US5447912A (en) | 1989-09-18 | 1995-09-05 | Senetek, Plc | Erection-inducing methods and compositions |
DE69105323T2 (en) | 1990-03-27 | 1995-06-01 | Bioelastics Res Ltd | Bioelastomeric drug delivery system. |
DE69101187T2 (en) | 1990-06-26 | 1994-09-29 | Sanwa Kagaku Kenkyusho Co | VIP analogues and their use. |
JPH07108232B2 (en) | 1990-10-09 | 1995-11-22 | エム・ディ・リサーチ株式会社 | Method for producing peptide or protein |
US5235041A (en) | 1990-12-28 | 1993-08-10 | Protein Polymer Technologies, Inc. | Purification of structurally ordered recombinant protein polymers |
US5595732A (en) | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
JPH05238950A (en) | 1991-04-22 | 1993-09-17 | Sanwa Kagaku Kenkyusho Co Ltd | Readily absorbable vip pharmaceutical |
US5958881A (en) | 1991-04-25 | 1999-09-28 | Korman; Louis Y. | Composition containing VIP for injection and a method of enhancing visualization of tissues during medical procedures |
US5681816A (en) | 1992-04-24 | 1997-10-28 | Korman; Louis Y. | Method of inducing temporary paralysis of the gastrointestinal tract during medical procedure |
US5288514A (en) | 1992-09-14 | 1994-02-22 | The Regents Of The University Of California | Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support |
US5545617A (en) | 1993-11-12 | 1996-08-13 | The Schepens Eye Research Institute, Inc. | Therapeutic regulation of abnormal conjunctival goblet cell mucous secretion |
US5705483A (en) | 1993-12-09 | 1998-01-06 | Eli Lilly And Company | Glucagon-like insulinotropic peptides, compositions and methods |
US5900405A (en) | 1994-01-24 | 1999-05-04 | Bioelastics Research, Ltd. | Polymers responsive to electrical energy |
CA2187322A1 (en) | 1994-04-07 | 1995-10-19 | Israel Rubinstein | Vasoactive intestinal polypeptide |
US5527610A (en) | 1994-05-20 | 1996-06-18 | The Uab Research Foundation | Elastomeric polypeptide matrices for preventing adhesion of biological materials |
US6004782A (en) | 1995-04-14 | 1999-12-21 | Bioelastics Research Ltd. | Hyperexpression of bioelastic polypeptides |
US5972406A (en) | 1995-04-14 | 1999-10-26 | Bioelastics Research Ltd. | Bioelastomers suitable as food product additives |
US5624711A (en) | 1995-04-27 | 1997-04-29 | Affymax Technologies, N.V. | Derivatization of solid supports and methods for oligomer synthesis |
US6037321A (en) | 1995-05-03 | 2000-03-14 | Biostar Inc. | Fusion proteins comprising vasoactive intestinal peptide or PACAP |
CA2230557A1 (en) | 1995-09-01 | 1997-03-13 | University Of Washington | Interactive molecular conjugates |
US5702717A (en) | 1995-10-25 | 1997-12-30 | Macromed, Inc. | Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers |
CN1300173C (en) | 1996-02-09 | 2007-02-14 | 艾博特生物技术有限公司 | Human antibodies that bind huma TNF 'alpha' |
US5816259A (en) | 1997-01-13 | 1998-10-06 | Rose; Samuel | Method for the diagnosis and treatment of cancer by the accumulation of radioactive precipitates in targeted cells |
US20020099003A1 (en) | 1997-10-28 | 2002-07-25 | Wilson Leland F. | Treatment of female sexual dysfunction with vasoactive agents, particularly vasoactive intestinal polypeptide and agonists thereof |
US6703359B1 (en) | 1998-02-13 | 2004-03-09 | Amylin Pharmaceuticals, Inc. | Inotropic and diuretic effects of exendin and GLP-1 |
US6998387B1 (en) | 1998-03-19 | 2006-02-14 | Amylin Pharmaceuticals, Inc. | Human appetite control by glucagon-like peptide receptor binding compounds |
FR2776520B1 (en) | 1998-03-25 | 2000-05-05 | Sod Conseils Rech Applic | NOVEL PHARMACEUTICAL COMPOSITIONS FOR THE SUSTAINED RELEASE OF PEPTIDES AND THEIR PREPARATION PROCESS |
ES2138561B1 (en) | 1998-04-17 | 2000-07-01 | Univ Madrid Complutense | USE OF VIP PEPTIDES AND PACAP IN THE TREATMENT OF ENDOTOXIC SHOCK IN MAMMALS. |
US6153655A (en) | 1998-04-17 | 2000-11-28 | Enzon, Inc. | Terminally-branched polymeric linkers and polymeric conjugates containing the same |
US20020151458A1 (en) | 1998-04-17 | 2002-10-17 | Perez Gomariz Rosa Maria | Method for treating and preventing septic shock with VPAC1R, VPAC2R and PAC1R agonists |
US6200598B1 (en) | 1998-06-18 | 2001-03-13 | Duke University | Temperature-sensitive liposomal formulation |
US6541033B1 (en) | 1998-06-30 | 2003-04-01 | Amgen Inc. | Thermosensitive biodegradable hydrogels for sustained delivery of leptin |
US6406921B1 (en) | 1998-07-14 | 2002-06-18 | Zyomyx, Incorporated | Protein arrays for high-throughput screening |
AU3867400A (en) | 1999-03-19 | 2000-10-09 | Duke University | Methods of using bioelastomers |
US20090175821A1 (en) | 1999-05-17 | 2009-07-09 | Bridon Dominique P | Modified therapeutic peptides with extended half-lives in vivo |
JP2004500906A (en) | 1999-11-12 | 2004-01-15 | ルーベン, レオ | Cardiac device for electrical and chemical modulation and vasoactive intestinal peptide for treatment of cardiopulmonary disorders |
US6235264B1 (en) | 1999-12-01 | 2001-05-22 | General Electric Company | Medical imaging method for characterizing tumor angiogenesis using polymeric contrast agents |
JP2001161363A (en) | 1999-12-03 | 2001-06-19 | Hisamitsu Pharmaceut Co Inc | Novel endoplasmic localization protein, agent for curing abnormal glycoprotein disease containing the same, dna coding for the protein and gene curing agent for curing abnormal glycoprotein disease containing the same |
US6593394B1 (en) | 2000-01-03 | 2003-07-15 | Prosperous Kingdom Limited | Bioactive and osteoporotic bone cement |
US7833992B2 (en) | 2001-05-18 | 2010-11-16 | Merck Sharpe & Dohme | Conjugates and compositions for cellular delivery |
US20050255554A1 (en) | 2000-03-20 | 2005-11-17 | Ashutosh Chilkoti | Fusion peptides isolatable by phase transition |
US6852834B2 (en) | 2000-03-20 | 2005-02-08 | Ashutosh Chilkoti | Fusion peptides isolatable by phase transition |
HU229108B1 (en) | 2000-06-16 | 2013-09-30 | Lilly Co Eli | Glucagon-like peptide-1 analogs |
SI1355942T1 (en) | 2000-12-07 | 2009-02-28 | Lilly Co Eli | Glp-1 fusion proteins |
MXPA03005135A (en) | 2000-12-13 | 2003-12-04 | Lilly Co Eli | Chronic treatment regimen using glucagon-like insulinotropic peptides. |
AU2002308706A1 (en) | 2001-06-01 | 2002-12-16 | Eli Lilly And Company | Glp-1 formulations with protracted time action |
EP1423133B1 (en) | 2001-08-15 | 2009-01-14 | Brown University Research Foundation | Treatment of muscular dystrophies and related disorders |
HUP0501192A3 (en) | 2001-08-23 | 2006-06-28 | Lilly Co Eli | Glucagon-like peptide-1 analogs |
CN1315531C (en) | 2001-11-06 | 2007-05-16 | 千寿制药株式会社 | Remedies for dry eye and diseases associated with dry eye |
US20060241028A1 (en) | 2002-06-10 | 2006-10-26 | Dorian Bevec | Use of compounds having the biological activity of vasoactive intestinal peptide for the treatment of sarcoidosis |
WO2004048401A1 (en) | 2002-11-27 | 2004-06-10 | Itoham Foods Inc. | Peptides and medicinal compositions containing the same |
EP1633382A4 (en) | 2003-05-14 | 2009-08-05 | Dow Corning | Repeat sequence protein polymer active agent conjugates, methods and uses |
JP2007524592A (en) | 2003-06-03 | 2007-08-30 | ノボ・ノルデイスク・エー/エス | Stabilized pharmaceutical peptide composition |
AU2004255379B2 (en) | 2003-07-14 | 2007-08-16 | Mondobiotech Ag | Biologically active substance of a vasoactive intestinal peptide for treating interstitial lung infections |
WO2005014030A1 (en) | 2003-07-24 | 2005-02-17 | Lutz-Henning Block | Method for treating lung diseases associated with ventilation-perfusion mismatches |
US7776815B2 (en) | 2004-02-24 | 2010-08-17 | Wisconsin Alumni Research Foundation | Use of neuropeptides for ligament healing |
US7928059B2 (en) | 2004-02-24 | 2011-04-19 | Wisconsin Alumni Research Foundation | Use of neuropeptides for traumatic cartilage injury |
US20050203009A1 (en) | 2004-03-12 | 2005-09-15 | Bayer Pharmaceuticals Corporation | VPAC1 selective antagonists and their pharmacological methods of use |
MXPA06011242A (en) | 2004-03-29 | 2007-01-16 | Univ Arizona | Amphipathic glycopeptides. |
CA2567635A1 (en) | 2004-05-21 | 2005-12-01 | Eli Lilly And Company | Selective vpac2 receptor peptide agonists |
JP4824682B2 (en) | 2004-06-11 | 2011-11-30 | ベクタス・バイオシステムズ・リミテッド | Compositions and methods for the treatment of cardiovascular disease |
US20080085860A1 (en) | 2004-08-18 | 2008-04-10 | Eli Lilly And Company | Selective Vpac2 Receptor Peptide Agonists |
WO2006023358A1 (en) | 2004-08-18 | 2006-03-02 | Eli Lilly And Company | Selective vpac2 receptor peptide agonists |
JP2008515437A (en) | 2004-10-08 | 2008-05-15 | フォーブス メディ−テック(リサーチ) インコーポレーテッド | Vasoactive intestinal polypeptide drug |
US20080312156A1 (en) | 2005-01-18 | 2008-12-18 | Duke University | In-Situ Crosslinkable Elastin-Like Polypeptides for Defect Filling in Cartilaginous Tissue Repair |
US7723472B2 (en) | 2005-02-28 | 2010-05-25 | The Regents Of The University Of California | Extracellular matrix binding chimeric proteins and methods of use thereof |
US7582608B2 (en) | 2005-10-26 | 2009-09-01 | Eli Lilly And Company | Selective VPAC2 receptor peptide agonists |
DE602006012358D1 (en) | 2005-11-18 | 2010-04-01 | Dabur Pharma Ltd | TARGETED FUSION PROTEINS FOR CANCER THERAPY |
NZ597677A (en) | 2005-12-09 | 2013-05-31 | Vectus Biosystems Ltd | Vip fragments and methods of use |
US8841255B2 (en) | 2005-12-20 | 2014-09-23 | Duke University | Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides |
WO2007073486A2 (en) | 2005-12-20 | 2007-06-28 | Duke University | Methods and compositions for delivering active agents with enhanced pharmacological properties |
US20130172274A1 (en) | 2005-12-20 | 2013-07-04 | Duke University | Methods and compositions for delivering active agents with enhanced pharmacological properties |
US7709227B2 (en) | 2006-01-04 | 2010-05-04 | Phasebio Pharmaceuticals, Inc. | Multimeric ELP fusion constructs |
US8367626B2 (en) | 2006-05-12 | 2013-02-05 | Wisconsin Alumni Research Foundation | Elastin-like polymer delivery vehicles |
EP2152741B1 (en) | 2007-05-21 | 2011-09-21 | Res International Sarl | Peptides with improved properties having the biological activity of vasoactive intestinal peptide (vip) and their use for the treatment of lung diseases |
US8933197B2 (en) | 2007-08-15 | 2015-01-13 | Amunix Operating Inc. | Compositions comprising modified biologically active polypeptides |
US20110207673A1 (en) | 2007-11-20 | 2011-08-25 | Ashutosh Chilkoti | Methods and compositions for modulating drug-polymer architecture, pharmacokinetics and biodistribution |
WO2009135184A2 (en) | 2008-05-01 | 2009-11-05 | The Trustees Of Columbia University In The City Of New York | Methods for treating and/or preventing cardiomyopathies by erk or jnk inhibition |
EP2307038A4 (en) | 2008-06-27 | 2013-03-27 | Univ Duke | Therapeutic agents comprising elastin-like peptides |
US20110219462A1 (en) | 2008-07-15 | 2011-09-08 | Bayer Schering Pharma Aktiengesellschaft | G-Protein Coupled Receptor 30 (GPR30) transgenic animals as a model for cardiovascular diseases |
US9333235B2 (en) | 2008-10-22 | 2016-05-10 | Trustees Of Dartmouth College | Combination therapy and kit for the prevention and treatment of cystic fibrosis |
NZ592687A (en) | 2008-10-23 | 2013-04-26 | Vertex Pharma | Modulators of cystic fibrosis transmembrane conductance regulator |
US20110288001A1 (en) | 2008-12-18 | 2011-11-24 | Homayoun Sadeghi | Biologically active proteins activatable by peptidase |
EP2496245B1 (en) | 2009-11-02 | 2016-07-20 | The Administrators Of The Tulane | Analogs of pitutary adenylate cyclase-activating polypeptide (pacap) and methods for their use |
EP2671889B1 (en) | 2010-04-02 | 2018-09-12 | The Regents Of The University Of Michigan | RF amide-related peptides and methods thereof |
CN103260647A (en) | 2010-11-30 | 2013-08-21 | 伦敦健康科学中心研究公司 | EGFR antagonist for the treatment of heart disease |
CN103476405A (en) | 2011-02-07 | 2013-12-25 | 持田制药株式会社 | Therapeutic agent for diastolic congestive heart failure |
HUE047354T2 (en) | 2011-05-18 | 2020-04-28 | Vertex Pharmaceuticals Europe Ltd | Deuterated derivatives of ivacaftor |
CA2873553C (en) | 2011-06-06 | 2020-01-28 | Phasebio Pharmaceuticals, Inc. | Use of modified vasoactive intestinal peptides in the treatment of hypertension |
EP4295858A1 (en) | 2011-08-24 | 2023-12-27 | ImmunoForge Co., Ltd. | Formulations of active agents for sustained release |
AU2012346058A1 (en) | 2011-11-28 | 2014-06-12 | Phasebio Pharmaceuticals, Inc. | Therapeutic agents comprising insulin amino acid sequences |
ES2656321T3 (en) | 2012-05-17 | 2018-02-26 | I.E.R.F.C. European Institute For Cystic Fibrosis Research | Combined therapy for cystic fibrosis |
US20150152170A1 (en) | 2012-05-23 | 2015-06-04 | Valerion Therapeutics, Llc | Methods for increasing muscle contractility |
US10159741B2 (en) | 2012-05-25 | 2018-12-25 | National Cheng Kung University | Methods and compositions comprising hyaluronan for enhancing bone marrow cell therapy |
US20150290328A1 (en) | 2012-11-20 | 2015-10-15 | Phasebio Pharmaceuticals, Inc. | Formulations of active agents for sustained release |
WO2014113434A1 (en) | 2013-01-15 | 2014-07-24 | Phasebio Pharmaceuticals, Inc. | Therapeutic agents, compositions, and methods for glycemic control |
ES2818824T3 (en) | 2014-05-08 | 2021-04-14 | Phasebio Pharmaceuticals Inc | Compositions comprising a VIP-ELP fusion protein for use in the treatment of cystic fibrosis |
US10722590B2 (en) | 2014-11-21 | 2020-07-28 | Phasebio Pharmaceuticals, Inc. | ELP fusion proteins for controlled and sustained release |
ES2822598T3 (en) | 2015-02-09 | 2021-05-04 | Phasebio Pharmaceuticals Inc | Methods and Compositions for Treating Muscle Diseases and Disorders |
-
2012
- 2012-06-06 CA CA2873553A patent/CA2873553C/en active Active
- 2012-06-06 ES ES12796397.3T patent/ES2669190T3/en active Active
- 2012-06-06 EP EP12796397.3A patent/EP2717902B1/en active Active
- 2012-06-06 US US14/124,612 patent/US9561262B2/en active Active
- 2012-06-06 WO PCT/US2012/041092 patent/WO2012170524A1/en active Application Filing
-
2013
- 2013-03-07 NO NO13710262A patent/NO2822914T3/no unknown
-
2016
- 2016-09-26 US US15/276,151 patent/US10940182B2/en active Active
Patent Citations (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4132746A (en) | 1976-07-09 | 1979-01-02 | University Of Alabama, Birmingham Medical & Education Foundation | Synthetic elastomeric insoluble cross-linked polypentapeptide |
US4187852A (en) | 1976-07-09 | 1980-02-12 | The University Of Alabama | Synthetic elastomeric insoluble cross-linked polypentapeptide |
US4474851A (en) | 1981-10-02 | 1984-10-02 | The University Of Alabama In Birmingham | Elastomeric composite material comprising a polypeptide |
US4500700A (en) | 1981-10-02 | 1985-02-19 | The Board Of Trustees Of The University Of Alabama For The University Of Alabama In Birmingham | Elastomeric composite material comprising a polypentapeptide having an amino acid of opposite chirality in position three |
US4589882A (en) | 1983-09-19 | 1986-05-20 | Urry Dan W | Enzymatically crosslinked bioelastomers |
US4605641A (en) | 1984-10-09 | 1986-08-12 | Hoffmann-La Roche Inc. | Synthetic vasoactive intestinal peptide analogs |
US4734400A (en) | 1984-10-09 | 1988-03-29 | Hoffmann-La Roche Inc. | Synthetic vasoactive intestinal peptide analogs |
US4870055A (en) | 1986-04-17 | 1989-09-26 | University Of Alabama At Birmingham | Segmented polypeptide bioelastomers to modulate elastic modulus |
US4835252A (en) | 1987-02-26 | 1989-05-30 | The Salk Institute Biotechnology/Industrial Associates, Inc. | Vasoactive intestinal peptide analogs |
US4939224A (en) | 1987-02-26 | 1990-07-03 | The Salk Institute Biotechnology/Industrial Associates, Inc. | Vasoactive intestinal peptide analogs |
US5766883A (en) | 1989-04-29 | 1998-06-16 | Delta Biotechnology Limited | Polypeptides |
US5141924A (en) | 1989-06-30 | 1992-08-25 | Hoffmann-La Roche, Inc. | Synthetic vasoactive intestinal peptide analogs |
US5520672A (en) | 1991-04-19 | 1996-05-28 | Urry; Dan W. | Superabsorbent materials and uses thereof |
US5677419A (en) | 1991-10-11 | 1997-10-14 | Hoffmann-La Roche Inc. | Cyclic vasoactive peptide analogs |
US5972883A (en) | 1993-03-16 | 1999-10-26 | Yeda Research And Development Co. Ltd. | Method for the treatment of neurodegenerative diseases by administering VIP, an analogue, fragment or a conjugate thereof |
WO1996032406A1 (en) | 1995-04-14 | 1996-10-17 | Bioelastics Research Ltd. | A simple method for the purification of a bioelastic polymer |
US6080837A (en) | 1996-02-09 | 2000-06-27 | Hoffmann-La Roche Inc. | Synthesis of VIP analog |
US6316593B1 (en) | 1996-02-09 | 2001-11-13 | Hoffmann-La Roche Inc. | Synthesis of VIP analog |
US6063061A (en) | 1996-08-27 | 2000-05-16 | Fusion Medical Technologies, Inc. | Fragmented polymeric compositions and methods for their use |
US6699294B2 (en) | 1998-02-27 | 2004-03-02 | Bioelastics Research, Ltd. | Injectable implants for tissue augmentation and restoration |
US6608174B1 (en) | 2000-02-18 | 2003-08-19 | Dabur Research Foundation | Radiolabeled vasoactive intestinal peptide analogs for diagnosis and radiotherapy |
US6489297B1 (en) | 2000-02-18 | 2002-12-03 | Dabur Research Foundation | Vasoactive intestinal peptide analogs |
US7094755B2 (en) | 2000-02-18 | 2006-08-22 | Dabur Research Foundation | Vasoactive intestinal peptide analogs |
US6753311B2 (en) | 2000-06-23 | 2004-06-22 | Drexel University | Collagen or collagen-like peptide containing polymeric matrices |
US20080221041A1 (en) * | 2000-11-28 | 2008-09-11 | Lutz-Henning Block | Compounds with the biological activity of vasoactive intestinal peptide for the treatment of pulmonary and arteriolar hypertension |
US7176278B2 (en) | 2001-08-30 | 2007-02-13 | Biorexis Technology, Inc. | Modified transferrin fusion proteins |
US7238667B2 (en) | 2001-12-21 | 2007-07-03 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US20080261863A1 (en) * | 2004-06-12 | 2008-10-23 | Bayer Pharmaceuticals Corp | Pegylation of Vasoactive Intestinal Peptide (Vip) / Pituitary Adenylate Cyclase Activating Peptide (Pacap) Receptor 2 (Vpac2) Agonists and Methods of Use |
US20070009602A1 (en) | 2005-06-24 | 2007-01-11 | Setton Lori A | Direct drug delivery system based on thermally responsive biopolymers |
WO2008030968A2 (en) | 2006-09-06 | 2008-03-13 | Phase Bioscience, Inc. | Fusion peptide therapeutic compositions |
WO2011020091A1 (en) | 2009-08-14 | 2011-02-17 | Phasebio Pharmaceuticals, Inc. | Modified vasoactive intestinal peptides |
Non-Patent Citations (16)
Title |
---|
BURHOL ET AL., SCAND J GASTROENT, vol. 13, 1978, pages 807 - 813 |
CARRETERO ET AL., CIRCULATION, vol. 101, 2000, pages 329 - 35 |
CLIFTON: "Methods in Molecular Biology", vol. 3, 1985, HUMANA PRESS, article "New Protein Techniques" |
DELGADO ET AL., PHARMACOL. REVIEWS, vol. 56, no. 2, 2004, pages 249 - 290 |
DOMSCHKE ET AL., GUT, vol. 19, 1978, pages 1049 - 53 |
EGAN ET AL., JAMA, vol. 303, no. 20, 2010, pages 2043 - 2050 |
GREG T. HERMANSON: "Bioconjugate Techniques", 1995, ACADEMIC PRESS, INC. |
LUNDBLAD: "Techniques in Protein Modification", 1995, CRC PRESS |
MORI ET AL., JPN HEART J., vol. 34, 1993, pages 785 - 94 |
NILSSON ET AL., ANN REV BIOPHYS BIO STRUCTURE, vol. 34, 2005, pages 91 - 118 |
ONUNE ET AL., EUR. J. PHARM. BIOPHARM., 2009 |
ONYUKSEL ET AL., PEPTIDES, vol. 27, 2006, pages 2271 - 5 |
POZO D ET AL., PEPTIDES, vol. 28, no. 9, 2007, pages 1833 - 1846 |
SAID ET AL., CIRCULATION, vol. 115, 2007, pages 1260 - 8 |
SIMONCSITS ET AL., EUR. J. BIOCHEM., vol. 178, no. 2, 1988, pages 343 - 350 |
TATUSOVA ET AL., FEMS MICROBIOL LETT., vol. 174, 1999, pages 247 - 250 |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9700598B2 (en) | 2009-08-14 | 2017-07-11 | Phasebio Pharmaceuticals, Inc. | Modified vasoactive intestinal peptides |
US10940182B2 (en) | 2011-06-06 | 2021-03-09 | Phasebio Pharmaceuticals, Inc. | Use of modified vasoactive intestinal peptides in the treatment of hypertension |
WO2014028776A1 (en) * | 2012-08-15 | 2014-02-20 | Zyngenia, Inc. | Monovalent and multivalent multispecific complexes and uses thereof |
US11052132B2 (en) | 2014-05-08 | 2021-07-06 | Phasebio Pharmaceuticals, Inc. | Methods and compositions for treating cystic fibrosis |
EP3256151A4 (en) * | 2015-02-09 | 2018-08-22 | Phasebio Pharmaceuticals, Inc. | Methods and compositions for treating muscle disease and disorders |
US10688156B2 (en) | 2015-02-09 | 2020-06-23 | Phasebio Pharmaceuticals, Inc. | Methods and compositions for treating muscle disease and disorders |
US11266719B2 (en) | 2015-02-09 | 2022-03-08 | Phasebio Pharmaceuticals, Inc. | Methods and compositions for treating muscle disease and disorders |
WO2017152399A1 (en) * | 2016-03-09 | 2017-09-14 | 兰州大学 | Fusion protein of vasoactive intestinal peptide and preparation method and use thereof |
Also Published As
Publication number | Publication date |
---|---|
EP2717902A4 (en) | 2015-01-14 |
EP2717902A1 (en) | 2014-04-16 |
CA2873553C (en) | 2020-01-28 |
EP2717902B1 (en) | 2018-01-24 |
US10940182B2 (en) | 2021-03-09 |
US9561262B2 (en) | 2017-02-07 |
CA2873553A1 (en) | 2012-12-13 |
US20150111829A1 (en) | 2015-04-23 |
US20170072021A1 (en) | 2017-03-16 |
NO2822914T3 (en) | 2018-10-06 |
ES2669190T3 (en) | 2018-05-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10940182B2 (en) | Use of modified vasoactive intestinal peptides in the treatment of hypertension | |
AU2017279636B2 (en) | Modified Vasoactive Intestinal Peptides | |
US8557769B2 (en) | Co-administration of FGF-21 and GLP-1 to treat diabetes and lower blood glucose | |
CA2909045C (en) | Therapeutic peptides | |
TWI353250B (en) | Glp-1 pharmaceutical compositions | |
WO2008056726A1 (en) | Glp-1 derivative and use thereof | |
CN115226391A (en) | Triazolotriazole co-agonists of glucagon and GLP-1 receptor | |
CN114867742A (en) | Stapled lactam co-agonists of glucagon and GLP-1 receptor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12796397 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14124612 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2873553 Country of ref document: CA |